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ABSTRACT 
 
Babesia microti Recombinant DNA Vaccine as a Model for Babesia bovis Prevention. 
(December 2009) 
Juliette E. Carroll, B.S., Tarleton State University 
Chair of Advisory Committee: Dr. Patricia J. Holman 
 
 Babesiosis is caused by a genus of tick-transmitted apicomplexan parasites with 
considerable economic, medical, and veterinary impact.  Bovine babesiosis is an 
important impediment to livestock production throughout the world.  Limited options are 
available for control of this widespread protozoal disease.  This study evaluated the 
protective effect of DNA vaccines incorporating Babesia cysteine proteases and Apical 
Membrane Antigen-1 separately and in combination. The Helios Gene Gun System was 
used to vaccinate BALB/c mice with plasmid DNA constructs encoding different 
B. microti proteins (pBmCP1, pBmAMA1 or a combination of pBmCP1 and 
pBmAMA1). An analysis of the parasitemia post-challenge supports the hypothesis that 
pBmCP1 and pBmAMA1 induce protective effects against the progression of the 
parasite.  However, the combination of the two constructs given simultaneously has no 
marked effect on parasite progression. Furthermore, the data obtained from the packed 
cell volumes of the mice indicates that only BmCP1 is able to reduce this effect of 
clinical disease with any level of significance. Babesia bovis constructs containing 
Cysteine Protease-2 and Apical Membrane Antigen-1 were created and sequence 
 iv 
verified for use in future vaccination studies. The results seen using the mouse model of 
Babesiosis may provide applicable information for the design of vaccines against other 
Babesia spp., particularly for B. bovis.  
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1.  INTRODUCTION 
 
Members of the genus Babesia are tick-vectored intraerythrocytic parasites of the 
phylum Apicomplexa, order Piroplasmida (Levine, 1971; Allsopp et al., 1994). Babesia 
species infect a wide variety of mammalian hosts including humans. Currently, there are 
over 100 recognized species of Babesia throughout the globe, five of which infect cattle: 
Babesia bovis, Babesia bigemina, Babesia divergens, Babesia major and Babesia ovata 
(Levine, 1985; Krause, 2002; Liu et al., 2008). 
The first Babesia sp. was described in the late 19th century by Hungarian scientist 
Victor Babes (Reviewed by Hunfeld et al., 2008). Babes discovered microorganisms in 
the erythrocytes of Romanian cattle suffering from hemoglobinuria, this pathogen would 
later be named Babesia bovis. Following its initial discovery, Smith and Kilborne were 
able to identify ticks as the source of infection for Babesia spp. This was a significant 
advance in both veterinary and human medicine, as it was the first time an arthropod was 
identified as the vector for disease (Smith and Kilborne, 1893).  
Toward the end of the nineteenth century ranchers throughout the world began to 
experience devastating losses among their cattle. Cattle throughout the Americas, 
Australia, and Africa were becoming infected by what was discovered to be bovine 
babesiosis, commonly referred to as ―Tick Fever‖ (Bock et al., 2004).  
 
 
____________ 
This thesis follows the style of Veterinary Parasitology. 
 2 
 Babesia bovis and Babesia bigemina became the most commonly recognized 
disease agents of bovine babesiosis in cattle located in tropical and subtropical regions of 
the world (Brown and Palmer, 1999).  
Babesia bovis and B. bigemina share similar biological characteristics - both are 
transmitted by the same tick vector and infect the erythrocytes of cattle. However, the 
clinical disease caused by these two parasites is remarkably different (Wright et al., 
1988; Criado-Fornelia et al., 2004). Generally, B. bovis is considered to be the more 
pathogenic of the two organisms, resulting in higher mortality rates among susceptible 
cattle (Brown and Palmer, 1999; Wright et al., 1988; Callow, 1984).  Both forms of 
babesiosis are characterized by high fever, anemia, ataxia, anorexia, haemoglobinurea 
and hypotensive shock. In contrast to B. bigemina infections, B. bovis infections are 
commonly associated with severe central nervous system (CNS) signs.  The damage 
done to the CNS is linked to sequestration of infected erythrocytes in the capillary bed of 
neural endothelial cells (Wright et al., 1988; O'Connor et al., 1999; Brown et al., 2006a). 
This rare phenomenon also makes B. bovis infections difficult to detect because of the 
low numbers of parasites circulating in peripheral blood (Fahrimal et al., 1992).  
 Accumulation and adherence of parasitized erythrocytes to organ vasculature is 
notably the most important aspect of B. bovis infections, however, the severe virulence 
of B. bovis has also been attributed to the overproduction of the pro-inflammatory 
cytokines associated with protective immunity resulting in a partially immune-mediated 
response (Brown et al., 2006b).  Together these two factors make B. bovis an 
 3 
economically devastating parasite with the potential to cause significant production 
losses among cattle producers.   
 In North America parasitism by cattle fever ticks is associated with two species 
of the family Ixodidae, Boophilus annulatus and Boophilus microplus (Bock et al., 2004; 
Estrada-Peña and Venzal, 2006). It should be noted that a recent change has been made 
with regards to the naming of these two species of ticks, transferring five species in the 
genus Boophilus into the genus Rhipicephalus (Horak et al., 2003). To avoid confusion 
this paper will retain the name Boophilus as a subgenus of Rhipicephalus (Murell and 
Barker, 2003). 
Populations of Boophilus ticks were linked to a widespread occurrence of bovine 
babesiosis throughout the southern United States shortly after Smith and Kilborne 
published their detailed findings that identified ticks as the vector of this devastating 
pathogen.  Epidemiologists believe these ticks were introduced into North America on 
cattle and horses transported to the New World by Spanish colonialists (George et al., 
2002).   
 
1.1  Life cycle and development of Babesia bovis in the tick vector 
Babesia bovis parasites are transmitted by larval ticks of the subgenus Boophilus 
(Mahoney and Mirre, 1979). Adult female Boophilus ticks acquire B. bovis while 
feeding on the erythrocytes of infected cattle. After the tick has fed to repletion, Babesia 
gametocyte development occurs in the tick gut. Gametogenesis leads to zygote 
formation followed by progression into the kinete stage (Mackenstedt et al., 1995).  The 
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motile kinete enters the hemolymph via penetration of the intestinal epithelium and 
begins to invade the tissues of the female tick, the most notable tissue of invasion being 
the ovaries (Howell et al., 2007). From the ovaries, kinetes are transmitted to the tick 
offspring through the egg.  Because Boophilus ticks are one-host ticks, meaning larval, 
nymphal, and adult development occur on the same host animal, transovarial 
transmission ensures that the parasite will be spread to the next tick generation 
(Mahoney and Mirre 1979; Howell et al., 2007). 
  After an adult female tick has mated and taken a blood meal she drops off the 
host and deposits infected eggs in the environment. Larvae hatch from the eggs 
approximately 21 days after ovipositing and have the ability to survive for long periods 
of time without feeding (Needham and Teel, 1991; Corson et al., 2004). In larvae 
Babesia sporozoites migrate to and develop within the salivary glands (Mehlhorn and 
Schein, 1984; Sauer et al., 1995).  Eventually larvae attach to the bovine host then 
development continues to the adult stage. Babesia bovis sporozoites are only transmitted 
to cattle by larval ticks; the tick cannot retain the infection following its first molt.  
 Tick saliva contains various anticoagulatory, anti-inflammatory and 
immunosuppressive components that increase the efficiency of sporozoite transmission 
to the host (Bowman et al., 1997). Infective sporozoites penetrate the host erythrocytes 
where they become trophozoites divide into merozoites. Merozoites exit the infected 
erythrocyte, enter the bloodstream and invade new erythrocytes in which they undergo 
asexual division (Bock et al., 2004). 
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The merozoite stage has characteristic features not found in trophozoites. These 
features include anterior secretory organelles known as rhoptries that are critical for cell 
invasion and an actomyosin motor driven inner membrane complex that is thought to 
propel the parasite into new cells (Lew et al., 2002; Yokoyama et al., 2002). 
Apicomplexans utilize rhoptry proteins secreted from organelles located at the apical end 
of merozoites for host cell invasion. Extracellular merozoites attach to the host 
erythrocyte, reorient to bring the apical organelles close to the attachment interface, and 
discharge rhoptry proteins onto the cell membrane (Yokoyama et al., 2002). 
Erythrocyte invasion is accomplished by a novel form of locomotion called 
gliding motility. Although they do not have cilia or flagella, Babesia merozoites are 
motile. They have the ability to glide on solid substrates, such as the host cell surfaces 
(Menard, 2001). Gliding motility is thought to be driven by an actomyosin-based system 
associated with the inner membrane complex found beneath the parasite plasma 
membrane (Lew et al., 2002; Zhou et al., 2006). This theory is supported by studies that 
show the inability of Toxoplasma and Plasmodium parasites to glide and invade host 
cells in the presence of actomyosin inhibitors (Dobrowolski and Sibley, 1996; Pinder, 
1998). Lew and others (2002) inhibited B. bovis parasite invasion in vitro using myosin 
and actin-binding drugs. This was the first reported case of actomyosin-based 
participation in erythrocyte invasion by B. bovis parasites. 
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1.2 Tick eradication efforts 
One of most economically destructive outbreaks of bovine babesiosis in the 
United States occurred in 1868 when apparently healthy cattle from Texas were 
relocated to stockyards in northern states. As a result, 15,000 head of native cattle from 
Illinois and Indiana were said to have contracted Babesia and died from the subsequent 
infections (Dolman, 1969; Pelzel, 2005).  
 Despite being heavily infested with ticks, Texas cattle often remained clinically 
normal. It was later discovered that cattle driven from Texas had previously acquired 
immunity to the disease due to frequent vector exposure as calves. Calves less than 6 
months of age possess a strong resistance against B. bovis diesase (Goff et al., 2001; 
Brown et al., 2006a). Exposure to the parasite during this period induces a long-lasting 
carrier state and concomitant immunity that prevents disease typically seen in 
susceptible adults upon initial infection with B. bovis. Cattle located in the northern 
states had not been previously exposed to the parasite as calves, making them highly 
susceptible to disease. The United States Congress estimated that the direct and indirect 
economic loss associated with bovine babesiosis during this period to be $130.5 million 
(approximately $3 billion today) (Dolman, 1969; APHIS, 2002).  
 Soon after this outbreak it was discovered that as infested Texas cattle advanced 
north, female Boophilus ticks would detach and distribute Babesia infected eggs (Bram 
and Gray 1983; APHIS, 2002; Pelzel, 2005). This prompted northern stockmen and 
ranchers to ban Texas cattle from export into their states. The U.S. Secretary of 
Agriculture placed strict quarantines on Texas cattle during summer months to prevent 
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the spread of the vector. Cattlemen quickly felt the crippling financial effects of the 
quarantines and turned to the Texas legislature. In 1893, the Livestock Sanitary 
Commission (now the Texas Animal Health Commission) was established to prevent the 
spread of tick fever. 
In 1906, as part of the Cattle Fever Tick Eradication Program (CFTEP), state- 
federal quarantine and eradication programs were established to eliminate cattle fever 
ticks from the United States. Laws were instated that required cattle to be systematically 
immersed in acaricide solution in concrete dipping vats. Cattle in endemic areas were 
dipped before being transported to any tick-free zone, especially northern markets 
(Graham and Hourrigan., 1977; Pelzel, 2005). 
By 1943 the two species of fever ticks, Bo. annulatus and Bo. microplus, were 
successfully eradicated from the United States, with the exception of a permanent 
quarantine zone between Texas and Mexico. Currently, tick riders employed by the U.S. 
Department of Agriculture's (USDA) Animal and Plant Health Inspection Service 
(APHIS) are responsible for maintaining the permanent quarantine zone, which extends 
852-square miles from Del Rio, TX to Brownsville, TX and encompasses eight South 
Texas counties (Hillman, 2008a). The goal of an APHIS tick inspector is to prevent the 
introduction of new ticks from Mexico (APHIS, 2002; Hillman, 2008a). This is 
accomplished by horseback patrol and systematic quarantines along the buffer zone.  
Tick inspectors capture stray Mexican cattle that have entered the country 
illegally or native cattle that may have crossed into Mexico and returned.  Surveillance 
and control rely on a process called ―scratching‖ for ticks. This requires the official to 
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inspect the skin of the animal with his fingers, feeling for ticks (Bram and Grey, 1983; 
Pelzel, 2005). If cattle are found to be infested with Boophilus ticks they are quarantined 
and dipped in 0.3% - 0.25% Coumaphos, an organophosphate acaricide, every 10 to 14 
days (EPA, 1996, Miller et al., 2005).  Once cattle are re-inspected and declared tick-free 
they may be moved out of quarantine. The Texas Animal Health Commission 
complements the USDA control efforts through tick inspection of livestock outside the 
quarantine zone and trace-out work at Texas livestock markets.  
Recent literature indicates that Boophilus tick populations in Mexico have 
developed resistance to organophosphate acaricides, the only approved chemicals for use 
in the cattle dipping vats in the U.S. (Jamroz et al., 2000; Li et al., 2003). Rodriguez-
Vivas and others (2006) reported that 83.7% of Bo. microplus ticks obtained from cattle 
in Yucatan, Mexico were confirmed resistant to organophosphates as well as other 
classes of acaricides. Evidence obtained by the USDA indicates that the resistant strains 
of ticks from Mexico are spreading into southern Texas and jeopardizing the tick 
eradication program (Jamroz, 2000; Miller et al., 2005; Davey, 2006).  
In August 2004, ticks obtained from cattle in Starr County, TX were examined 
for resistance to several types of acaricides including Coumaphos using the Larval 
Packet DD Test (FAO, 1971). Engorged females were collected from native cattle and 
held in growth chambers until they produced eggs. Once egg production was complete, 
larvae were allowed to develop. On day 14 of larval development a discriminating dose 
test was performed with various concentrations of coumaphos, permethrin and amitraz.  
Resistance was detected by exposing larvae to an acaricide concentration expected to kill 
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99% of susceptible ticks, then increasing the dose to an amount twice that expected to 
kill 99% of susceptible ticks.  
The results from these bioassays revealed that the acaricide resistance levels of 
ticks collected from Texas cattle were similar to those found in ticks from Mexican 
cattle (Miller et al., 2005). This is the first published report of organophosphate-resistant 
ticks in the U.S. (George et al., 2002, Davey et al, 2006). 
According to the 2007 Veterinary, Medical and Urban Entomology Annual 
Report, an additional 1000 square miles extending over five Texas counties has been 
placed under temporary quarantine due to the presence of Boophilus ticks (Everett, 
2008). Re-establishment of the tick from Mexico appears to be related to the movement 
of white-tailed deer and exotic ungulates along the Texas-Mexico border (George, 1989; 
Bram et al., 2002). Boophilus microplus in all life stages have been recovered from wild 
deer, demonstrating that deer may serve as an alternative host for these ticks (Kistner 
and Hayes, 1970).  Treatment options for wildlife are limited to a bait system, which 
applies a pyrethroid to the animal, and ivermectin treated corn, which must be 
discontinued at least 60 days prior to hunting season (Hillman, 2008b). However, 
acarcide resistance may limit the effectiveness of these treatment options. 
The estimated cost of eliminating new infestations along the recently expanded 
quarantine region is $13 million (Everett, 2008). In March 2008, the U.S. Department of 
Agriculture’s Animal and Plant Health Inspection Service awarded the Cattle Fever Tick 
Eradication Program a $5.2 million dollar grant to be spent on the control of cattle fever 
tick outbreaks in the U.S. Although this amount is significantly less than requested it 
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will provide supplementary surveillance, training and treatments to postpone re-
infestation for the time being (Everett, 2008). 
Should bovine babesiosis re-emerge in the United States, the effects on the cattle 
industry will be that of a severe economic impact. Texas is the number one cattle 
producing state in the country, with an inventory of 13.8 million cattle and calves 
(NASS, 2007). For Texas cattle alone, direct and indirect losses associated with B. bovis 
have been estimated at $1.5 billion within the first year of re-emergence (Teel and 
Wagner, 2001).  
At this time the only effective prevention of bovine babesiosis in the United 
States is the use of intensive tick control measures such as quarantine zones and 
scrupulous surveillance. These methods are extremely costly and labor intensive. Due to 
the development of acaricide-resistant tick populations and the increased number of 
wildlife carrying these ticks into tick-free areas, it is only a matter of time before 
alternative babesiosis prevention strategies must be employed.  
 
1.3 Host immune response  
Young cattle possess a unique spleen-dependent innate immunity to babesiosis 
that lasts until approximately 6 months of age. Animals infected within this timeframe 
exhibit a persistent yet milder form of the infection (Trueman and Blight, 1978; 
Mahoney et al., 1979). Contrarily, aged cattle develop severe clinical disease signs upon 
initial exposure to Babesia (Mahoney and Ross, 1972; Mahoney et al., 1973; Goff, et al., 
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2001). The phenomenon of age-related immunity allows cattle infected as calves to 
transmit the parasite throughout their lifetime without the ill effects of the disease.  
Originally the age-related innate immunity observed in older calves was 
attributed to the presence of protective antibodies transferred through colostrum of 
immune mothers (Mahoney 1967). Contrarily, Riek (1963) and Christensson (1987) 
reported the same form of immunity in calves from unexposed dams and in calves that 
did not receive colostrum at birth. It has been hypothesized that age-related immunity to 
B. bovis involves a soluble babesiacidal factor (Levy et al., 1982).  
Adler and others (1995) identified nitric oxide (NO) as the first babesiacidal 
molecule to contribute to arrested growth of the parasite. Gale et al. (1998) was able to 
significantly reduce the mean parasitemia of B. bovis infected cattle by treating them 
with aminoguanidine, an inhibitor of the inducible form of nitric oxide synthase (iNOS). 
Goff et al. (2001) showed that the occurrence of age-related non-specific immunity in 
calves was achieved by the rapid induction of splenic interleukin-12 (IL-12) and 
interferon-γ (IFN-γ) followed by iNOS mRNA expression in the spleen. In the same 
study involving adult cattle, IL-12 and IFN-γ occurred later and no iNOS could be 
recovered. This suggests different mechanisms for age-related innate immunity in calves 
versus the acquired (contaminant) immunity seen in older cattle (Brown et al., 2006a).  
Animals that have recovered from an acute B. bovis infection, either naturally or 
after treatment, are often referred to as ―immunologically primed‖ (Brown and Palmer, 
1999). These animals remain persistently infected and develop a protective immunity 
that prevents the onset of clinical signs upon re-exposure to the parasite. Because the 
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parasite  involves an extracellular and intracellular stage, the mechanisms required to 
maintain immunity against B. bovis infections are thought to rely on both cell-mediated 
responses and humoral antibody responses (Brown and Palmer, 1999; Homer et al., 
2000).  
Studies involving persistently infected, immune cattle suggested that merozoite 
antigens produced by the parasite induce a strong IFN-γ response from memory T helper 
type 1 cells (Th1), providing prolonged immunity (Brown and Palmer, 1999). 
Macrophages activated in presence of the parasite produce cytokines such as IFN- , IL-
12 and IL-18 that promotes IFN-γ production by CD4+ Th1 cells (Brown and Palmer, 
1999; Shoda et al., 2001). The role of IFN-γ is two-fold, it is required to further 
stimulate production of babesiacidal molecules by macrophages and to enhance the 
opsonizing of immunoglobulin G (IgG) antibodies (Estes and Brown, 2002). During the 
re-introduction of the parasite to the blood of an immune animal, immunoglobulin G 
(IgG) antibodies block erythrocyte invasion of the parasite by binding and neutralizing 
freely circulating sporozoites before they can reach host erythrocytes (Homer et al., 
2000).  
In vitro studies using lymphocytes from Babesia-immune cattle demonstrate that 
bovine CD4+ T cells produce IFN-γ in response to parasite antigen stimulation and that 
the development of acquired immunity against B. bovis in cattle is related to this specific 
cell-mediated response (Brown et al., 1993). Murine models of Babesia microti confirm 
the theory that CD4+ T lymphocytes rather than CD8+ T lymphocytes play an essential 
role in the elimination of the infections in mice.  
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As with B. bovis, acquired immunity to B. microti is thought to involve the 
activation of memory and effector CD4+ T cells that secrete IFN-γ and assist with the 
production of protective antibodies (Igarashi et al., 1994). Mice with depleted CD4+ T 
cell levels are more susceptible to infection with B. microti compared to mice with 
adequate CD4+ T cell levels (Shimada et al., 1996; Igarashi et al., 1999).  Similarly, in 
the closely related protozoan Plasmodium, Stephens and Langhorne (2007) 
demonstrated that CD4+ T cells were essential for parasite clearance in malaria. 
 
1.4 Vaccination strategies 
An alternative approach to strategic tick control is becoming increasingly 
important with regards to B. bovis infections.  Sole reliance on one form of prevention is 
unrealistic, while integrating the use of acaricides with an appropriate vaccine will prove 
to be a better choice for the control bovine babesiosis (de Waal and Combrink, 2006). 
The first Babesia vaccine was developed through the use of a live attenuated 
strain of B. bovis (Callow and Mellors, 1966; Callow and Tammemacli, 1967; Callow, 
1979). Blood of carrier animals was passaged into splenectomized calves resulting in 
reduced virulence of the parasite. Although this type of vaccine has been successfully 
used to control babesiosis in many parts of the world, it induces a carrier state, allowing 
the animal to serve as a reservoir for transmission. The live annulated vaccine has a 
number of other deficiencies including, a short shelf life of 5-7 days at 5ºC, potential for 
reversion to virulence, and the possibility of co-transmission of other infectious agents 
such as viruses and haemoprotozoan parasites (Wright and Riddles, 1989). Vaccines 
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derived from killed B. bovis strains have also been employed (Mahoney et al., 1981) 
however, they were unsuccessful because of the unsatisfactory level of immunity 
produced (Timms et al., 1983).  
Passive transfer studies show that antibodies play an important role in the 
prevention of bovine babesiosis (Mahoney, 1967). Antibodies bind to critical epitopes 
found on the surface of the merozoites and block the processes required for erythrocyte 
invasion and/or parasite replication (Heins et al., 1995, Brown et al., 2006b). Knowledge 
of this type of antibody production has driven vaccine development towards the use of 
functionally relevant merozoite antigens (Heins et al., 1995).  
To overcome the difficulties seen with the production of live Babesia vaccines a 
variety of soluble parasite exoantigens has been isolated from B. bovis as potential 
vaccine candidates (Sibinovic et al., 1967; Goodger et al., 1987; Montenegro-James et 
al., 1987). Exoantigens are shed by the parasite during merozoite invasion of 
erythrocytes and can be obtained through the blood or plasma of Babesia infected 
animals or the supernatant of in vitro Babesia cultures (James, 1989). The use of parasite 
exoantigens appears to induce an immune response that decreases clinical disease 
manifestations through the rapid development of protective antibodies (Schetters et al., 
2001). Early use of single strain exoantigen vaccines produced protection against the 
antigen-derived strain but failed to provide protection against different strains upon 
challenge (Wright et al., 1983; Goodger et al., 1987; Schetters et al., 1995).   
Schetters et al. (2001) obtained promising vaccine results against canine 
babesiosis by using exoantigens obtained from a combination of culture-derived Babesia 
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canis canis and Babesia canis rossi. This study concluded that dogs immunized with a 
bivalent vaccine had an effective antibody response and reduced clinical signs upon 
challenge from both forms (Schetters et al., 2001).  
Although studies indicate that exoantigens do confer some protection against 
Babesia, a specific individual exoantigen has yet to be isolated. Additionally, soluble 
parasite exoantigens require the use of cultured parasites or infected animals, making 
them difficult to obtain in large quantities. These drawbacks have resulted in a shift 
towards an alternate type of subunit vaccine. The use of recombinant proteins from 
cloned DNA has come to the forefront of Babesia vaccine research because of their 
stability and high reproducibility. 
 Proteins produced from micronemes, rhoptries, and dense granules at the apical 
end of the parasites are thought to play a major role in invasion of erythorocytes and 
establishment of infection by apicomplexan parasites (Dubremetz et al., 1998).  
Recognition of the host cell is initiated by receptor-ligand interactions, while entry into 
the host erythrocyte is initiated by contact between the apex of the parasite and the 
surface of the cell (Yokoyama et al., 2006). After contact with the red blood cells, the 
parasite will orient itself to allow the apical membrane to enter the cell first. A tight 
junction is then formed, permitting the parasite to invade the red blood cell and asexually 
reproduce. After division, the parasite exits the erythrocyte and travels through the blood 
where it can enter a new cell and undergo another round of division (Dubremetz et al., 
1998).  
 16 
Protective immunity against babesiosis may be directed against one or more 
surface antigens associated with the merozoite. Antibodies in sera obtained from cattle 
recovered from B. bovis and B. bigemina infections have been used to identify numerous 
surface-labelled merozoite proteins (McElwain et al., 1988; Suarez et al., 1991; Jasmer 
et al., 1992; Wilkowsky et al., 2003). In B. bovis, the most well-documented surface 
proteins are those which belong to the family of variable merozoite surface antigens 
(VMSA) including 60-kDa rhoptry-associated protein 1 (RAP-1), 42-kDa merozoite 
surface antigen-1 (MSA-1), and 44-kDa MSA-2c. RAP-1 antigen, a member of a 
polymorphic gene family, have undoubtedly been the most intensely studied of all the 
VMSAs.  
Conservation of B-cell and T-cell epitopes among various B. bovis strains 
initiated interest in RAP-1 as vaccine candidate (Brown et al., 1996).  Babesia bovis 
RAP-1 is encoded by two identical RAP-1 genes and possesses a sequence homologous 
to that of RAP-1 found in other Babesia spp. (Suarez et al., 1998; Dalrymple et al., 
1993). Using a lysate of merozoites, Yokoyama and others (2002) showed binding of 
RAP-1 to bovine erythrocytes in an erythrocyte-binding assay. In addition to the proof of 
RAP-1 binding to the erythrocyte in that assay, anti-RAP-1 antibodies were successful in 
hindering the binding of the parasite to the host erythrocyte in vitro. However, Norimine 
et al. (2003) found no evidence of protective immunity using a RAP-1 recombinant 
vaccine in cattle, even though the vaccine initiated strong cell-mediated and humoral 
responses against RAP-1.   
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 MSA-1 showed promise as a vaccine because of its ability to neutralize 
merozoite infectivity in vitro, suggesting its importance in merozoite invasion (Hines et 
al., 1992). As seen with RAP-1, recombinant MSA-1 immunization also failed to confer 
protection against challenge with virulent B. bovis (Hines et al., 1995). MSA-2c has been 
identified as being highly conserved among different B. bovis strains and serves as a 
possible vaccine candidate. Like MSA-1, bovine antibodies to recombinant MSA-2c 
neutralized the invasion of erythrocytes by B. bovis (Wilkowsky et al., 2003). In vivo 
vaccine trials have yet to be completed. 
 
1.5 Apical Membrane Antigen – 1 as a vaccine target 
 Because of the availability of genomic sequences of B. bovis, recombinat vaccine 
candidates can be identified based on their genetic identity with homologous proteins of 
other apicomplexan parasites (Brayton et al., 2007). Apical Membrane Antigen-1 
(AMA-1) is a highly conserved micronemal surface protein found among members of 
the phylum Apicomplexa, including B. bovis, Toxoplasma gondii and all species of 
Plasmodium examined to date (Waters et al., 1990; Donahue et al., 2000; Gaffar et al., 
2004). In Plasmodium, AMA-1 is stored in the microneme organelles and expressed 
during merozoite formation in maturing schizonts where it is transported to the rhoptries 
prior to erythrocyte invasion. While the specific function of AMA-1 is not yet known, it 
is thought to be directly responsible for reorientation of the apical end or junctional 
contact of the parasite with the host cell, which is dependent on binding proteins for 
completion of the parasite (Kocken et al., 2000; Gaffar et al., 2004; Mitchell et al., 
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2004). Because of its pivotal role in erythrocyte invasion, AMA-1 is a leading malaria 
vaccine candidate (Girard, et al., 2007; Nair, 2002). 
While the overall amino acid similarity between Plasmodium AMA-1 and 
B. bovis AMA-1 is low (18%), characteristic features such as an N-terminal ectoplasmic 
region, a cysteine-rich ectodomain, a single transmembrane domain, and a C-terminal 
cytoplasmic tail are found in both proteins (Chesne-Seck et al., 2005).  The important 
structural similarities between B. bovis AMA-1 and Plasmodium AMA-1 suggest that 
much of the research done with Plasmodium may be applied to B. bovis (Gaffar et al., 
2004; Chesne-Seck et al., 2005).  
Mice and non-human primates immunized with the ectodomain of Plasmodium 
AMA-1 are reported to have an increased protective immunity against challenge from 
blood-stage parasites (Anders et al., 1998; Hodder et al., 2001; Stowers et al., 2002). 
Evidence of this AMA-1 initiated immune response suggests that the protein could be a 
successful candidate for inclusion in a Babesia vaccine. Gaffer et al. (2004) identified 
B. bovis AMA-1 as a low-abundance 82-kDa protein that is synthesized into a 69-kDa 
protein upon invasion of erythrocytes in vitro. Additionally, antiserum made against 
B. bovis AMA-1 prevented parasite invasion of host erythrocytes in vitro.  
As in the case with soluble parasite exoantigens, considerable antigenic 
polymorphism could limit the effectiveness of a recombinant AMA-1 vaccine when 
challenged under field conditions. Immunization with the highly polymorphic 
Plasmodium falciparum AMA-1 induces antibodies that block the growth of the 
homologous parasite but are less efficient in blocking the growth of heterologous 
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P. falciparum (Kennedy, 2002; Duan et al., 2008). To date, no variation has been shown 
in AMA-1 within Babesia spp. Studies in our lab comparing AMA-1 from four different 
B. microti strains have shown no difference among the amino acid sequences 
(unpublished results).       
 
1.6 Cysteine proteases as a vaccine target 
Cysteine proteases are known for their importance in propagation and 
proliferation of protozoan parasites (McKerrow, 1993; Holman et al., 2002; Sajid and 
McKerrow, 2002). Meirelles et al. (1992) demonstrated that cysteine protease-specific 
inhibitors prevent host cell invasion and arrest intracellular development of 
Trypanosoma sp. in vitro. Engel et al. (1998) went on to report the first successful 
treatment of Chagas' disease in an animal model using inhibitors designed to inactivate 
cruzain, the major cysteine protease of T. cruzi, the causative agent of Chagas’ disease. 
Plasmodium falciparum contains several cysteine proteases with various 
functions including hydrolysis of hemoglobin, erythrocyte rupture and erythrocyte 
invasion (Rosenthal, 2004). Hemoglobin digestion is the best characterized function of 
Plasmodium cysteine proteases and is thought to provide amino acids for parasite protein 
synthesis, allow space in the cell for the growing parasite and maintain the osmotic 
stability of parasites (McKerrow, 1993; Lew et al., 2003). Incubating cultured malaria 
parasites with cysteine protease inhibitors blocked the ability of the parasite to process 
hemoglobin therefore reducing its proliferation (Rosenthal, 1995).  
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In order to complete the erythrocytic cycle of Plasmodium, the parasite must 
rupture the infected erythrocyte and release merozoites. Plasmodium cysteine protease 
inhibitors inhibit the rupture of the erythrocytes preventing the continuation of the 
asexual cycle (Wickham et al., 2003). Additionally, Greenbaum et al. (2002) 
demonstrated the role of cysteine proteases in Plasmodium erythrocyte invasion by using 
inhibitors to block invasion of erythrocytes by merozoites.  
Holman et al. (2002) identified the gene cys-1, which codes for a cathepsin L-like 
cysteine protease found in Babesia equi. In that study membrane permeable cysteine 
protease inhibitor E64d was shown to inhibit parasite propagation of B. equi in vitro, 
suggesting a target for vaccine development. Similar results were reported by Okubo et 
al. (2007) in which E64d significantly inhibited erythrocyte invasion activity of B. bovis 
in vitro. Although the exact role of cysteine protease in Babesia infections is not clear, 
data strongly suggest it plays an important role in erythrocyte invasion and/or replication 
of Babesia. 
 
1.7 Study design 
Because of the critical role AMA-1 plays in host cell invasion and the effect of 
cysteine protease on parasite proliferation, they have been selected as target genes for 
inclusion in a recombinant vaccine against B. bovis infection. Our first objective was to 
generate and verify plasmid constructs containing B. bovis AMA-1 and cysteine protease 
genes. Once it was established that these constructs could be obtained in vitro, a vaccine 
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utilizing Babesia microti AMA-1 and B. microti cysteine protease-1 (CP-1) constructs 
was created to test the efficacy of these targets as a model for the B. bovis vaccine. 
The main focus of current malaria vaccines is the use of DNA technology. 
Multivalent DNA vaccines incorporate the cell-mediated and humoral roles of the 
immune system, both of which are required for optimal protective effects. Genes coding 
for different antigenic regions of malaria proteins have been successful in invoking 
strong immune responses against the parasite (Jones et al, 2001; Ivory and Chadee, 
2004; Wang et al., 2004; Coban et al., 2004). Antigenic variation and the complex nature 
of the parasite life cycle allow for varied responses to natural infection. The use of a 
multivalent vaccine consisting of two antigens presents a greater number of protective 
epitopes and a stronger cell-mediated response.  Studies using a multivalent vaccine 
against leishmaniasis proved that the combination of three antigens is more effective in 
stimulating CD4+ Th1 cells and reducing parasite numbers than that of a single antigen 
(Mendez et al., 2001; Rafati et al., 2001). By targeting different parasite systems it is 
anticipated that we will be able to prevent invasion and proliferation of the parasite in 
the host, inhibiting the onset of clinical signs. 
For this study, the eukaryotic expression vector, pCMV (Gene Therapy Systems, 
CA), will be used to generate recombinant plasmid DNA constructs. This vector has 
been modified to incorporate a CD5 secretory signal and a polypeptide protein tag 
(FLAG-tag) to the genes of interest, and the resultant vector is designated 
pCMVCD5flag (McIlhinney, 2004; Edwards and Aruffo, 1993). Addition of a FLAG-
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tag allows fusion proteins to be purified by affinity chromatography and for evaluating 
protein expression using anti-Flag monoclonal antibodies. 
Plasmid DNA is an ideal vaccine vector because it is internalized by antigen 
presenting cells and can induce antigen presentation by major histocompatibility 
complex class II for T-cell response. The unmethylated CpG dinucleotide motifs found 
in the plasmid DNA backbone readily induce Th1 cytokine expression and increase the 
antigen-specific production of IFN-γ. This increased IFN-γ production enhances the 
development of cell-mediated responses against the immunizing antigens (Klinman et 
al., 1999). The pCMVCD5flag vector contains cytomegalovirus (CMV) promoter that 
drives gene expression and is widely used for high-level protein expression in 
mammalian cells (Boshart et al., 1985; Foecking and Hofstetter, 1986; Nott et al., 2003). 
The route of pDNA delivery plays an important role in the immunogenicity and 
efficacy of the vaccine. The skin is an ideal target for DNA immunization because of the 
large numbers of resident cutaneous antigen presenting cells, such as Langerhans cells 
and dermal dendritic cells. Intradermal gene vaccination induces antigen specific Th1 
cells secreting high levels of IFN-γ and stimulating the production of IgG2a isotype 
antibody (Grunathan and Klinman, 2000). The use of a biolistic device (e.g. a gene gun) 
to propel plasmid DNA-coated gold particles into the epidermis has been reported to be 
more effective at eliciting a protective immune response than intramuscular or 
intraperitoneal delivery methods (Yoshida et al., 2000; Mohamed et al., 2003). Upon 
challenge, a single gene gun vaccination using 2 μg of Toxoplasma gondii HSP70 gene 
resulted in a significant reduction in the number of T. gondii organisms compared with 
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50 μg of T. gondii HSP70 given by intramuscular or intraperitoneal injection (Mohamed 
et al., 2003). Biolistic delivery of DNA to the skin using the gene gun resulted in the 
direct transfection of dendritic cells and subsequent migration to draining lymph nodes 
(Akbari et al., 1999; Larregina and Falo, 2000; Larregina et al., 2001). 
The vaccine designed in this study will utilize biolistic delivery of pDNA 
encoding B. microti AMA-1 and CP-1 via the Helios Gene Gun System (Bio-Rad). Gold 
particles will be coated with plasmid DNA, and the coated particles will then be 
accelerated into the epidermis of BALB/c mice using a compressed helium driven gene 
gun.  
Anesthetized mice will receive a series of 3 injections at 2-week intervals. Each 
injection will contain 2 μg of pDNA encoding for AMA-1 and/or CP-1, or control 
plasmid DNA. It is anticipated that the AMA-1 and CP-1 protein will be expressed by 
antigen presenting cells, stimulating a strong CD4+ IFN- γ effector/memory T-cell 
response directed towards the inhibition of AMA-1 and CP-1 when challenged by 
infection with B. microti parasites. By targeting AMA-1 and CP-1, we hope to prevent 
parasite invasion of the host erythrocytes and arrest parasite proliferation. By disrupting 
the parasite, we can reduce parasitemia levels. If successful, this study will serve as a 
proof of concept for B. bovis vaccination and open the door to a new vaccine against 
bovine babesiosis. 
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1.8 Hypothesis 
Vaccination with Babesia derived Apical Membrane Antigen-1 and Cysteine 
Protease-1 will elicit a protective immune response against challenge infection. The null 
hypothesis being that there is no significant reduction of parsitemia between the 
vaccinated mice and the control mice. 
 
1.9 Objectives 
The objectives for this study are to: 
 
1. Generate and sequence verify plasmid constructs containing B. bovis AMA-1 
ectodomain and full-length cysteine protease. 
 
2. Generate and sequence verify plasmid constructs expressing B. microti  Apical 
Membrane Antigen-1 and Cysteine Protease-1 to be used as vaccine in a mouse 
model. 
 
3. Validate the use of Apical Membrane Antigen-1 and Cysteine Proteases as vaccine 
candidates for B. bovis using B. microti constructs in a mouse model. 
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2. MATERIALS AND METHODS 
 
2.1 DNA extraction from Babesia bovis 
 
 DNA was obtained from a cryo-preserved Mexican-isolate of in vitro cultivated 
Babesia bovis using the FlexiGene DNA Extraction method (Qiagen). The DNA 
concentration was adjusted to 100 ng/ul based on quantification using the NanoDrop 
ND-1000 Spectrophotometer (NanoDrop Technologies).  
 
2.2 Amplification of full-length Babesia bovis Cysteine Protease-2 
 Oligonucleotide primers for polymerase chain reaction (PCR) were designed 
based on the B. bovis (T2Bo Strain) cysteine protease-2 gene sequence (GenBank 
accession no. XP_001610695). The primers used for amplification of the full gene 
(1335 bp) were CP B.bov Forward (5′-ATG GGA ATA CCG GCT GCT GC-3′) and CP 
B.bov Reverse (5′-TTA ATA TGG GAC ATA ACC GTA AGA AAG AAC GC-3′) with 
an optimal annealing temperature of 63ºC (the table on p.31). To avoid nucleotide 
misincorporations during by PCR amplification, Phusion High-Fidelity DNA 
Polymerase was used (Finnzymes). The amplification profile for the PCR reaction was 
initial denaturation at 98ºC for 30 s, followed by 30 cycles of denaturation at 98ºC for 
10 s, annealing at 63ºC for 10 s and extension at 72ºC for 2 min with a final extension at 
72ºC for 10 min followed by hold at 4ºC (Hybaid PCR Express Thermocycler). The 
product was checked by electrophoresis on an ethidium bromide stained 1% agarose gel 
alongside a 100 bp DNA marker (Invitrogen). 
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Amplification with Phusion High-Fidelity DNA Polymerase does not result in 
the 3′ adenine overhangs required to ligate into the pCR-TOPO2.1 vector (Invitrogen); 
therefore, incubation of the PCR product with 2X Taq PCR Master Mix was required for 
addition of 3′ adenine overhangs. The Phusion High-Fidelity PCR amplicon was purified 
using the QIAquick PCR Purification method (Qiagen). The purified DNA was 
quantified on the NanoDrop ND-1000 Spectrophotometer at a concentration of 
106 ng/µl. The purified PCR product (10 µl) was incubated in 10 µl of 2X Taq PCR 
Master Mix (Qiagen) at 72ºC for 10 min. 
 
2.3 Cloning Babesia bovis Cysteine Protease-2 into pCR-TOPO2.1 and Champion 
pET 101 Directional TOPO vectors 
 A cloning reaction was prepared using 2 µl (53 ng/µl) of purified B. bovis 
cysteine protease PCR amplicon, 1 µl of salt solution, 2.0 µl of sterile water and 1 µl of 
pCR-TOPO2.1 vector according to the manufacturer’s instructions (Invitrogen). The 
reaction was gently mixed and allowed to incubate at room temperature for 30 min. 
Following the initial incubation, 2 µl of the cloning reaction was added to One Shot 
TOP10 Competent Escherichia coli cells (Invitrogen) and incubated on ice for 30 min. 
Following the 30 min incubation on ice, the cells were heat-shocked at 42ºC for 30 s and 
supplemented with 250 µl of S.O.C medium (0.5% Yeast extract, 2.0% tryptone, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM MgSO4, 20 mM glucose). The 
transformation mixture was shaken horizontally (200 rpm) at 37ºC for 1 h (Queue 
Orbital Shaker, Queue Systems, Inc) and spread onto pre-warmed LB agar plates (Luria 
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Bertoni Agar, Sigma-Aldrich) containing Kanamycin (final concentration 50 
µg/ml)(Sigma-Aldrich) and X-Gal (5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside, 
40 mg/ml, Fisher Scientific). The plates were then incubated at 37ºC overnight. 
 Transformants were analyzed by colony PCR to check for proper B. bovis 
cysteine protease insert. A master mix was made consisting of 300 µl of 2X Taq PCR 
Master Mix, 276 µl of sterile water, 12 µl of 1 pmol M13 Forward (-20) (5′-GTA AAA 
GCG CGG CCA G-3′) and 12 µl of 1 pmol M13 Reverse (5′-CAG GAA ACA GCT 
ATG AC-3′). A portion of each transformant colony was added to 20 µl of master mix in 
a 0.2 ml PCR tube. One tube containing 20 µl of master mix served as a negative 
control. The cycling program used was initial denaturation at 94ºC for 5 min, followed 
by 30 cycles of denaturation at 94ºC for 10 s, annealing at 50ºC for 1 min and extension 
at 72ºC for 2 min. A final extension at 72ºC for 10 min was followed by a 4ºC hold. The 
product was checked by electrophoresis on an ethidium bromide stained, 1% agarose gel 
alongside a 100 bp DNA Marker. Positive clones containing the desired B. bovis 
cysteine protease insert were expanded into 10 ml LB broth cultures containing 
Kanamycin and grown for 16 h with shaking (200 rpm). 
The broth culture was centrifuged (1800 rpm for 20 min) to pellet the bacteria, 
and the supernatant discarded. Babesia bovis cysteine protease pDNA was column-
purified from the pellet using the QIAprep Spin Miniprep method (Qiagen) and 
quantified using the NanoDrop ND-1000 Spectrophotometer.  The purified pDNA clones 
were sequenced using M13 Forward (-20) and M13 Reverse primers to obtain the full 
nucleotide sequence of the cysteine protease insert (Davis Sequencing, Inc. Davis, CA). 
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The sequencing reactions were performed using Applied Biosystems Big Dye 
Terminator V3.0 sequencing chemistry and the resulting sequences analyzed using 
Sequencher 3.0 software (Gene Codes Corporation). BLAST searches were performed 
on the nucleotide sequences to confirm the correct amino acid sequence (National Center 
for Biotechnology Information, National Institutes of Health 
(http://www.ncbi.nlm.nih.gob/BLAST/) (Altschul et al., 1990).  
The insert DNA from pCR-TOPO2.1 Clone 5 was identified as a 99% amino acid 
match for the B. bovis (T2Bo Strain) cysteine protease-2 gene sequence (GenBank 
accession no. XP_001610695) and subsequently used as the template DNA for ligation 
of the gene insert into the Champion pET 101 Directional TOPO vector (Invitrogen, 
Carlsbad, CA). A PCR reaction using Phusion High-Fidelity DNA Polymerase was 
performed with BbovCP(pET) forward primer (5′-CAC CAT GGA AAT ACC GGC 
TGC T-3′) and BbovCP(pET) reverse primer (5′-GAC ATA ACC GTA AGA AAG 
AAC GCC ACA T-3′) (the table on p.31). The amplification profile for the PCR reaction 
was initial denaturation at 98ºC for 30 s, followed by 30 cycles of denaturation at 98ºC 
for 10 s, annealing at 62ºC for 10 s and extension at 72ºC for 2 min with a final 
extension at 72ºC for 10 min followed by hold at 4ºC. The product was checked by 
electrophoresis on an ethidium bromide stained 1% agarose gel alongside a 100 bp DNA 
marker. Using the same method described with pCR-TOPO2.1 vector, the resulting PCR 
products were ligated into Champion pET 101 Directional TOPO vector and One Shot 
TOP10 Competent E. coli cells were transformed. Upon removal of the transformation 
reaction from the shaker, it was spread onto pre-warmed LB agar plates containing 
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Carbenicillin at a final concentration of 50 μg/ml(Research Products International 
Corporation) and incubated at 37ºC overnight. 
Transformants were analyzed by colony PCR to check for proper cysteine 
protease insert. A master mix of consisting of 400 µl of 2X Taq PCR Master Mix, 368 µl 
of sterile water, 16 µl of 1 pmol T7 Forward (5′-TAA TAC GAC TCA CTA TAG GG-
3′) and 16µl of 1 pmol T7 Reverse (5′-TAG TTA TTG CTC AGC GGT GG-3′). Plasmid 
purification was done as described with the pCR-TOPO2.1 vector and quantified using 
the NanoDrop ND-1000 Spectrophotometer. Six clones containing the proper cysteine 
protease insert were sequenced using T7 Forward and T7 Reverse primers to obtain the 
full nucleotide sequence (Davis Sequencing, Inc. Davis, CA). The sequencing reactions 
were performed using Applied Biosystems Big Dye Terminator V3.0 sequencing 
chemistry and BLAST searches (NCBI) performed on the obtained nucleotide sequences 
to identify the correct gene sequence in the proper orientation. 
 
2.4 Amplification of Babesia bovis Apical Membrane Antigen-1 (AMA-1) 
ectodomain 
 Primers were designed based on the B. bovis Apical Membrane Antigen-1 (T2Bo 
strain) (GenBank accession no. XM_001610993). Amplification of B. bovis AMA-1 
ectodomain (1737 bp) was carried out using Platinum Taq DNA High Fidelity 
Polymerase with forward primer BbovisAMAF2 (5′-GGC CAA CCA ATT CAC GC-3′) 
reverse primer BbovisR1 (5′-CAA TTG ATT AAC AAG CGA CCA CG-3′) (Table 1). 
The amplification profile for the PCR reaction was initial denaturation at 96ºC for 2 min, 
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followed by 30 cycles of denaturation at 96ºC for 10 s, annealing at 62ºC for 10 s and 
extension at 68ºC for 2 min with a final extension at 68ºC for 10 min followed by hold at 
4ºC. The product was checked by electrophoresis on an ethidium bromide stained 1% 
agarose gel, alongside a 100 bp DNA marker. 
 
2.5 Cloning Babesia bovis AMA-1 ectodomain into pCR-TOPO2.1 and Champion 
pET 101 Directional TOPO vectors 
Babesia bovis AMA-1 was cloned into the pCR-TOPO2.1 vector as described 
above for the B. bovis cysteine protease gene. Plasmid DNA from pCR-TOPO2.1 Clone 
4 was identified as a 99% amino acid match for B. bovis Apical Membrane Antigen-1 
(T2Bo strain) (GenBank accession no. XM_001610993) and subsequently used as the 
template DNA for ligation of the B.bovis AMA-1 ectodomain into the Champion pET 
101 Directional TOPO vector. A PCR reaction using Phusion High-Fidelity DNA 
Polymerase was performed with forward primer BbovAMASigPF (5′-CAC CAT GTC 
CAA CTC CAC ACT CTT C-3′) reverse primer BbovAMAmreP (5′-GAT ACG CTT 
TGT GTT GTA GAG TCC G-3′) and an internal primer BbovMRE (5′-GAT ACG CTT 
TGT GTT GTA GAG TCC-3′) (Table 1). The amplification profile for the PCR reaction 
was initial denaturation at 98ºC for 30 s, followed by 30 cycles of denaturation at 98ºC 
for 10 s, annealing at 59ºC for 10 s and extension at 72ºC for 1.5 min with a final 
extension at 72ºC for 10 min, followed by hold at 4ºC. The product was checked by 
electrophoresis on an ethidium bromide stained 1% agarose gel alongside a 100 bp DNA 
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marker. Cloning of the B. bovis AMA-1 into Champion pET 101 Directional TOPO was 
also performed as described above for B. bovis cysteine protease.  
 
Table 1  
  
Babesia bovis Full Length Cysteine Protease and Apical Membrane Antigen-1 
Ectodomain PCR Oligonucleotide Primers 
 
PCR Primer Sequence Annealing 
Temp. 
 
CP B.bov Foward  
 
CP B.bov Reverse 
 
BbovCP (pET) Forward 
  
BbovCP (pET) Reverse  
 
BbovisAMAF2  
 
BbovisR1  
 
BbovAMASigPF        
BbovAMAmreP 
BbovMRE  
 
5′-TGGGAATACCGGCTGCTGC-3′ 
 
5′- TATGGGACATAACCGTAAGAAAGAACGC-3′ 
 
5′-CACCATGGAAATACCGGCTGCT-3′ 
 
5′-GACATAACCGTAAGAAAGAACGCCACAT-3′ 
 
5′-GGCCAACCAATTCACGC-3′ 
 
5′-CAATTGATTAACAAGCGACCACG-3′ 
 
5′-CACCATGTCCAACTCCACACTCTTC-3′ 
 
5′-GATACGCTTTGTGTTGTAGAGTCCG-3′ 
 
5′-GATACGCTTTGTGTTGTAGAGTCC-3′ 
 
     
        63ºC 
 
63ºC 
 
62ºC 
 
62ºC     
 
62ºC 
 
 62ºC    
 
59ºC     
 
59ºC    
 
59ºC        
 
 
 
2.6 Amplification and cloning of Babesia microti Cysteine Protease-1 (CP-1) 
hydrophilic domain into pCR-TOPO2.1 and pCMVCD5flag vectors 
The hydrophilic domain of B. microti CP-1 (1113 bp) was amplified using 
Phusion High-Fidelity PCR from a previously cloned B. microti cysteine protease (CP-1) 
gene (Mahmoud et al., 2002 ) with primers carrying restriction sites for BamH1. The 
forward primer used was BmCPBAMH1FWD (5′-ATA GGA TCC TAT GGA GAC 
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TGA GGC TTC GAG AC-3′) and the reverse primer was BmCPBAMH1REV (5′-ATA 
GGA TCC TTA CAA CGG CAT TAA ACC G-3′). The amplification profile for the 
PCR reaction was initial denaturation at 93ºC for 3 min, followed by 35 cycles of 
denaturation at 93ºC for 30 s, annealing at 50ºC for 1 min and extension at 72ºC for 1.2 
min with a final extension at 72ºC for 10 min followed by hold at 4ºC. The PCR product 
was electrophoresed through a 0.8% agarose gel (Sigma-Aldrich) in 1X TAE buffer 
(0.04M Tris acetate; 0.001 M EDTA) at 50 volts for 1 hour. The appropriate sized 
amplicon was excised from the gel using a sterile scalpel and the amplicon purified from 
the gel slice using the QIAquick Gel Extraction method (Qiagen). 
A pCR-TOPO2.1 clone confirmed as carrying the B. microti CP-1 fragment was 
restriction digested with BamH1 (Fermentas), gel purified and the resulting fragment 
ligated into the respective sites of the BamH1-digested and tritrated pCMVCD5flag 
vector using T4 DNA ligase (Invitrogen, Carlsbad, CA). One Shot TOP10 Competent 
E. coli cells were transformed with the resulting BmCP-1 plasmids in the same manner 
as described above for B. bovis. The transformed cells were plated out onto LB agar 
plates containing Carbenicillin and incubated overnight at 37°C.  The BmCP-1 pDNA 
was column-purified using the QIAprep Spin Miniprep method and quantified using the 
NanoDrop ND-1000 Spectrophotometer. After purification the BmCP-1 plasmids were 
sequenced to identify which clones contained the correct gene sequence and orientation. 
Once the correct clone, designated pBmCP-1, was identified, a large quantity (~10mg) 
of BmCP-1 endotoxin-free plasmid DNA was obtained using the Qiagen EndoFree 
Plasmid Giga method (Qiagen). 
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2.7 Amplification and cloning of Babesia microti Apical Membrane Antigen-1 
(AMA-1) ectodomain into pCR-TOPO2.1 and pCMVCD5flag vectors 
The B. microti AMA-1 ectodomain (1440 bp) was previously amplified and 
cloned into the pCMVCD5flag vector using the same general methodology as described 
above for B. microti CP-1 and the resultant recombinant construct, designated 
pBmAMA-1, was available for this study.  The insert was sequence verified at the start 
of this study. 
 
2.8 Validation of gene expression by pBmAMA-1 and pBmCP-1 constructs 
Human embryonic kidney (HEK) Freestyle 293-A cells (Invitrogen) were 
transfected with the pBmAMA-1 or pBmCP-1 plasmid constructs to validate gene 
expression. For transfection, 2 µg plasmid DNA, 2 µl Turbofect transfection reagent 
(Fermentas) and 100 µl Opti-MEM 1 (GIBCO Laboratories) were mixed and incubated 
at room temperature for 15 min and pipetted into 6-well plate containing a monolayer of 
Freestyle 293-A cells. The 6-well plate was then incubated for 48 h at 37ºC in a 
humidified 8% CO2 in air atmosphere. 
Gene expression by the pBmAMA-1 and pBmCP-1 constructs was confirmed by 
immunocytometric analysis of transfected HEK 293-A cells by detecting the FLAG tag. 
The transfected HEK 293-A monolayers were methanol–fixed (-20°C, 5 min) and 
incubated with a 1/1000 dilution of a mouse anti-FLAG M2-alkaline phosphatase 
conjugate (Sigma-Aldrich) in blocking buffer [1X phosphate-buffered saline (PBS) with 
5% fetal bovine serum (FBS)]. Following five washes in blocking buffer, the buffer was 
removed and the alkaline phosphatase activity detected using Fast Red TR/Naphthol AS-
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MX substrate (SIGMA FAST; Sigma-Aldrich). To achieve this, one tablet of 0.1 M 
TRIS buffer was added to 10 ml deionized water and vortexed. A Fast Red TR/Naphthol 
AS-MX tablet was dissolved in the 10 ml TRIS buffer and filtered through a 0.45 μ 
syringe filter. Approximately 0.1 to 0.2 ml of Fast Red TR/Naphthol AS-MX solution 
was used to cover the cells. The cells were stained overnight and the reaction stopped by 
washing the cells with deionized water. The stained cells were visualized at 400 X 
magnification and photographed using an Olympus 1X70 inverted phase contrast 
microscope (Olympus Optical). 
 
2.9 Expression and purification of Babesia microti AMA-1 and CP-1 protein 
 
The B. microti CP-1 and AMA-1 recombinant proteins were produced by 
transient expression using the FreeStyle 293 Expression System (Invitrogen). The 293-F 
cells were cultured in suspension to a density of 1.2x106 cells per ml in the presence of 
FreeStyle 293 Expression Medium (Invitrogen). Lipid-DNA complexes were prepared 
by diluting 30 µg of pBmAMA-1 or pBmCP-1 constructs in 1 ml of Opti-MEM 1. 
Following a 5-min incubation, the DNA dilution was added to a 50 ml tube containing 
45 µl of 293fectin (Invitrogen) diluted in 1 ml of Opti-MEM 1 and incubated at room 
temperature for 20 min. The DNA-293Fectin mixture was added to a 40 ml 
FreeStyle293 cell suspension in a 250 mL polycarbonate disposable sterile Erlenmeyer 
flask (Fisher Scientific) and the transfected suspension was further incubated for 48 h at 
37°C on an orbital shaker platform rotating at 120-130 rpm. 
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The transfected 293-F cells were harvested by centrifugation in conical 
centrifuge tubes (2800 rpm for 10 min). The supernatant was decanted and saved. The 
cell pellets were resuspended in 300 µl of 1X protease inhibitor cocktail (Sigma-Aldrich) 
and lysed using three freeze/thaw cycles (alternately liquid nitrogen and a 37°C water 
bath). The lysed cell suspension was centrifuged at 2800 rpm for 15 min and the 
resulting supernatant combined with the saved supernatant and clarified through a 0.45 
µm filter. Forty milliliters of lysate was purified through batch absorption using Anti-
FLAG M2 Affinity Gel (Sigma-Aldrich). The protein was eluted from the affinity gel by 
acid elution using 1 ml aliquots of 0.1 M glycine HCL, pH 3.5 into vials containing 
25 µl of 1 M Tris, pH 8.0. The elution fractions were combined and concentrated by 
centrifugation using a 30kD molecular cut-off membrane (Millipore Corporation). The 
concentration of B. microti CP-1 or AMA-1 protein was determined using the BCA 
protein assay (Pierce Biotechnology). 
 
2.10 Validation of expressed protein using western blotting 
The molecular weights of the expressed B. microti CP-1 and AMA-1 proteins 
were confirmed by western blotting using anti-FLAG mAb. The proteins were resolved 
on a 10% Bis-Tris NuPAGE gel using the XCell Surelock electrophoresed and transfer 
apparatus with NuPAGE MES 1X Running Buffer (Invitrogen) at 135 volts for 1 h.  The 
electrophroesed proteins were transferred to a polyvinylidene difluoride (PVDF) 
membrane (Millipore) using NuPAGE transfer buffer at 35 volts for 1 h (Invitrogen). 
The PVDF membrane was first placed in blocking buffer (5% non-fat milk powder in 
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Tris-buffered saline containing 0.2% Tween 20 (TBS-T)) for 1 h at room temperature, 
and subsequently incubated in a 1:1000 dilution of monoclonal ANTI-FLAG M2 
Affinity Purified Antibody (Sigma-Aldrich) in blocking buffer for 1 h at room 
temperature.  The PVDF membrane was washed in TBS-T to removed unbound 
antibody, and then incubated with Immun-Star AP substrate (Bio-Rad) for 5 min.  The 
antibody–antigen complexes were visualized by exposure to subsequent development of 
BioMax chemiluminescence film (Kodak). 
 
2.11 Vaccine preparation 
For DNA immunization with the Helios Gene Gun System (Bio-Rad), each dose 
consisted of 0.5mg of gold spheres (1.6 µm) coated with plasmid DNA (2 µg of 
pBmAMA-1 or 2 µg of pBmCP-1, or 2 µg of each combined (4µg total) for the three 
experimental groups, respectively, resuspended in water). Gold spheres were suspended 
in 100µl of 0.05M spermidine in water. Following a 5 s sonication step the DNA was 
precipitated onto the gold by addition of 1 M CaCl2. The DNA–gold complex was 
incubated for 10 min at room temperature, centrifuged for 15 s, supernatant removed, 
and the gold washed three times with 500 µl 100% ethanol. After the last wash the pellet 
was resuspended in 0.05 mg/ml polyvinylpyrrolidone (PVP) in ethanol. The DNA-
coated gold was applied to the inner surface of Tefzel tubing (Helios Tubing Prep 
Station, Bio-Rad) by centrifugal force and a slight flow of nitrogen was used to 
evaporate the ethanol. The tubing was cut into cassettes, each containing a dose of 
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plasmid DNA. Cassettes containing the DNA-coated gold were loaded into the gene gun 
and the vaccine administered to the animals using compressed helium (Fig.1). 
 
2.12 Vaccination regimen 
 Four groups of 5 BALB/c mice each were used for this vaccine trial (Table 1). 
The abdomen of each animal was shaved and wiped with 70% ethanol. The spacer of the 
Helios Gene Gun was held directly against the abdominal skin (Fig. 1). The gun was 
discharged at a helium pressure of 300 psi. Mice were injected 3 times at 2-week 
intervals. Group 1 received inoculations containing 2 µg of pBmAMA-1 and 2 µg of 
pBmCP-1 pDNA (total 4 µg pDNA/injection). Group 2 received 2 µg of pBmAMA-1. 
Group 3 received 2 µg of pBmCP-1. Group 4 served as the negative control and received 
2 µg of the expression vector only (no gene inserts). During the first two series of 
inoculations, the mice were anesthetized to effect with isoflurane in oxygen. However, it 
became apparent that the act of anesthetizing the animals was more stressful than 
administering the vaccine without anesthetic. On the recommendation of the 
Comparative Medicine Program (Texas A&M University) a change was made to the 
protocol and the mice were not anesthetized for the third vaccination. 
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Fig. 1. Gene transfer into the abdominal skin of BALB/c mice using Helios Gene 
Gun.  
 
 
 
2.13 Analysis of infection following challenge with Babesia microti  
One month after the last gene gun vaccination was administered, the mice were 
challenged by intraperitoneal administration of 107 B. microti-infected red blood cells.  
The challenge dose was obtained from two infected C.B-17/IcrHsd-Prkdc-scid mice at a 
combined parasitemia of 65%, adjusted with Dulbecco’s phosphate buffered saline (pH 
7.4) to a concentration of 107 B. microti-infected red blood cells in 0.3 ml. The animals 
were monitored daily by obtaining blood smears from the tip of the tail, which were 
methanol-fixed and Giemsa-stained for microscopic examination at 1000X under oil 
immersion. Percent parasitemias were measured by counting the number of B. microti-
infected erythrocytes in 1000 erythrocytes.  The mean PCV of each group was 
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determined before challenge and every 5 days following challenge. Blood was collected 
from the tail tip in heparinized microhematocrit capillary tubes (Fisherbrand) and 
centrifuged (IEG MB Centrifuge); the PCV was then measured and recorded. The 
plasma was collected from the microhematocrit tubes and stored at –80º C for future 
serologic analysis (not in the scope of the current study).  After the parasitemia cleared, 
as determined by three consecutive days without parasite observation in blood smears, 
the mice were humanely euthanized. Euthanasia was effected by carbon dioxide 
asphyxiation followed by cervical dislocation. 
 
2.14 Statistical analyses 
A repeated data analysis was used to compare parasitemias and PCVs of 
vaccinated animal to unvaccinated animals. P-values < 0.05 are considered statistically 
significant. All data analyses were performed using SPSS version 12.0 (SPSS, Inc., 
2001, Chicago IL). 
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3. RESULTS 
3.1 Babesia bovis constructs 
The B. bovis Cysteine Protease-2 full open reading frame was successfully 
amplified (Fig. 2), cloned into pCR-TOPO2.1 and subcloned into the Champion pET 
Directional TOPO expression vector.  Figure 3 shows that the clone obtained was a 99% 
amino acid match to the B. bovis Cysteine Protease-2 sequence in the genome project 
(http://www.ncbi.nlm.nih.gob/BLAST/). The AMA-1 ectodomain gene region was 
successfully amplified (Fig. 4) and cloned into the pCR-TOPO2.1 and Champion pET 
101 Directional TOPO vectors. The clone obtained was a 99% amino acid match to the 
B. bovis AMA-1 sequence in the genome project (Fig. 5). The constructs were stored at 
–80ºC for future applications. 
 
   BP     1        2         3    
   
2072
1500
   500
  100  
Fig. 2 . PCR-amplified Babesia bovis Cysteine Protease gene product.  Amplification 
of  Babesia bovis cysteine protease (2), negative control (3), alongside 100 base pair 
marker (Invitrogen) (1). 
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BbCP1            MEIPAAASDLSNLDDHYVRSDDEVRDTTLIGRSRRCCVGKKTMWIVLLGTAILTAAITSG 
BbCP1Clone       MEIPAAASDLSNLDDHYVRSDDEVRDTTLIGRSRRCCVGKKTMWIVLLGTAILTAAITSG 
                 ************************************************************ 
 
BbCP1            IILLVTSLSGSKAKPSGGVKHIGKFDGLNRADCHVSPETFAELSSMAHLGEINVSDPAEI 
BbCP1Clone       IILLVTSLSGSKAKPSGGVKHIGKFDGLNRADCHVSPETFAELSSMAHLGEINVSDPAEI 
                 ************************************************************ 
 
BbCP1            VKYMDFTRMAKKFDRKYDTVAERHTAFLNFRRNHDIVKSHEHNKAATYTKDLNHFFDKDI 
BbCP1Clone       VKYMDFTRMAKKFDRKYDTVAERHTAFLNFRRNHDIVKSHEHNKAATYTKDLNHFFDKDI 
                 ************************************************************ 
 
BbCP1            KAVAAKLLHKIDVYNESNISVTPTDTTATKENQPIYATLKNYSVSAGYPPIGSKVNFEDI 
BbCP1Clone       KAVAAKLLHKIDVYNESNISVTPTDTTATKENQPIYATLKNYSVSAGYPPIGSKVNFEDI 
                 ************************************************************ 
 
BbCP1            DWRRADAVTPVKDQGMCGSCWAFAAVGSVESLLKRQKTDVRLSEQELVSCQLGNQGCNGG 
BbCP1Clone       DWRRADAVTPVKDQGMCGSCWAFAAVGSVESLLKRQKTDVRLSEQELVSCQLGNQGCNGG 
                 ************************************************************ 
 
BbCP1            YSDYALNYIKFNGIHRSEE-PYLAADGKCVAHDGTKYYIKGYHAAKGRSVANQLLVMGPT 
BbCP1Clone       YSDYALNYIKFNGIHRSEEWPYLAADGKCVAHDGTKYYIKGYHAAKGRSVANQLLVMGPT 
                 ******************* **************************************** 
 
BbCP1            VVYIAVSEDLMHYSGGVFNGECSDSELNHAVLLVGEGYDSALKKRYWLLKNSWGTSWGED 
BbCP1Clone       VVYIAVSEDLMHYSGGVFNGECSDSELNHAVLLVGEGYDSTLKKRYWLLKNSWGTSWGED 
                 **************************************** ******************* 
 
BbCP1            GYFRLERTNTPTDKCGVLSYGYV 
BbCP1Clone       GYFRLERTNTPTDKCGVLSYGYV 
                 *********************** 
 
Fig. 3. Alignment of predicted amino acid sequence of Babesia bovis Cysteine 
Protease gene insert (pCR-TOPO2.1) with the B. bovis T2Bo Strain Cysteine 
Protease-2 (GenBank accession no. XP_001610695). Amino acids identical in both 
sequences are indicated by stars (). 
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Fig. 4. PCR-amplified Babesia bovis AMA-1 gene product. Amplification of B. bovis 
AMA-1 (2), negative control (1), alongside 100 base pair DNA marker (Invitrogen) (3). 
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BbAMA1           MQSTSPKYNYKRMLCMVFVPVILSSFFAEDALASNSTLFAFHREPTNRRLTRRASRGQLL 
BbAMA1Clone      MQSTSPKYNYKRMLCMVFVPVILSSFFAEDALASNSTLFAFHREPTNRRLTRRASRGQLL 
                 ************************************************************ 
 
BbAMA1           NSRRGSDDTSESSDRYSGRSGGSKNSGQSPWIKYMQKFDIPRNHGSGIYVDLGGYESVGS 
BbAMA1Clone      NSRRGSDDTSESSDRYSGRSGGSKNSGQSPWIKYMQKFDIPRNHGSGIYVDLGGYESVGS 
                 ************************************************************ 
 
BbAMA1           KSYRMPVGKCPVVGKIIDLGNGADFLDPISSEDPSYRGLAFPETAVDSNIPTQPKTRGSS 
BbAMA1Clone      KSYRMPVGKCPVVGKIIDLGNGADFLDPISSEDPSYRGLAFPETAVDSNIPTQPKTRGSS 
                 ************************************************************ 
 
BbAMA1           SVTAAKLSPVSAKDLRRWGYEGNDVANCSEYASNLIPASDKTTKYRYPFVFDSDNQMCYI 
BbAMA1Clone      SVTAAKLSPVSAKDLRRWGCEGNDVANCSEYASNLIPASDKTTKYRYPFVFDSDNQMCYI 
                 ******************* **************************************** 
 
BbAMA1           LYSAIQYNQGNRYCDNDGSSEEGTSSLLCMKPYKSAEDAHLYYGSAKVDPDWEENCPMHP 
BbAMA1Clone      LYSAIQYNQGNRYCGNDGSSEEGTSSLLCMKPYKSAEDAHLYYGSAKVDPDWEENCPMHP 
                 ************** ********************************************* 
 
BbAMA1           VRDAIFGKWSGGSCVAIAPAFQEYANSTEDCAAILFDNSATDLDIEVVNEEFNELKELTS 
BbAMA1Clone      VRDAIFGKWSGGSCVAIAPAFQEYANSTEDCAAILFDNSATDLDIEVVNEEFNELKELTS 
                 ************************************************************ 
 
BbAMA1           GLKRLNLSKVANAIFSPLSNVAGTSRISRGVGMNWATYDKDSGMCALINETPNCLILNAG 
BbAMA1Clone      GLKRLNLSKVANAIFSPLSNVAGTSRISRGVGMNWATYDKDSGMCALINETPNCLILNAG 
                 ************************************************************ 
 
BbAMA1           SIALTAIGSPLEYDAVNYPCHIDTNGYVEPRAKTTNKYLDVPFEVTTALSTKTLKCNAYV 
BbAMA1Clone      SIALTAIGSPLEYDAVNYPCHIDTNGYVEPRAKTTNKYLDVPFEVTTALSTKTLKCNAYV 
                 ************************************************************ 
 
BbAMA1           HTKYSDSCGTYFLCSDVKPNWFIRFLHMIGLYNTKRIVIFVCCTTTAIVLTIWIWKRFIK 
BbAMA1Clone      HTKYSDSCGTYFLCSDVKPNWFIRFLHMIGLYNTKRIVIFVCCTTTAIVLTIWIWKRFIK 
                 ************************************************************ 
 
BbAMA1           AKKEPAPPSFDKYLSNYDYDTTLDADNETEQRLDSSAYSWGEAVQRPSDVTPVKLSKIN 
BbAMA1Clone      AKKEPAPPSFDKYLSNYDYDTTLDADNETEQRLDSSAYSWGEAVQRPSDVTPVKLSKIN 
                 *********************************************************** 
 
 
Fig. 5. Alignment of predicted amino acid sequence of Babesia bovis AMA-1 gene 
insert (pCR-TOPO2.1) with the B. bovis T2Bo strain AMA-1 (GenBank accession 
no. XM_001610993). Amino acids identical in both sequences are indicated by stars (). 
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3.2 BmCP-1 and BmAMA-1 plasmid constructs 
 
The B. microti Cysteine Protease-1 hydrophilic region was successfully 
amplified (Fig. 6), cloned into pCR-TOPO 2.1 and subcloned into the pCMVCD5flag 
expression vector.  Figure 7 shows that the clone obtained was a 100% amino acid match 
to the predicted B. microti CP-1 sequence previous identified in our lab (Mahmound et 
al., 2002). The AMA-1 ectodomain gene region was previously amplified and cloned 
into pCR-TOPO 2.1 and subcloned into the pCMVCD5flag expression vector.  The 
clone was sequenced verified to confirm a 100% amino acid match to the B. microti 
AMA-1 sequence previously identified in our lab (P.J. Holman, unpublished results) 
(Fig. 8). 
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Fig. 6. PCR-amplified Babesia microti CP-1 gene product. Amplification of 
B. microti CP-1 (3), negative control (1), 1 Kb marker (New England Bio Labs) (2). 
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B.microti CP-1 ETEASRQVKARLIDDMLSGQSLYNCYPYDQQRYHVGKPAQKPESVGEFIVRTLTEHGYTI 
BmCP-1 clone ETEASRQVKARLIDDMLSGQSLYNCYPYDQQRYHVGKPAQKPESVGEFIVRTLTEHGYTI 
  ************************************************************ 
 
B.microti CP-1 DPDLEAKIYKEFNIFMAKFGKIYFTPKEKGDKYINFRKSYEIVMAHNNNKNVSYKMALGQ 
BmCP-1 clone DPDLEAKIYKEFNIFMAKFGKIYFTPKEKGDKYINFRKSYEIVMAHNNNKNVSYKMALGQ 
  ************************************************************ 
 
B.microti CP-1 FSDKSPEEFENSVLNPMMSNEHYVNAIKSGRFNLFRPDPRQEGIPEQFIWDHKFLGPVLN 
BmCP-1 clone FSDKSPEEFENSVLNPMMSNEHYVNAIKSGRFNLFRPDPRQEGIPEQFIWDHKFLGPVLN 
  ************************************************************ 
 
B.microti CP-1 QGACGSCWAFATAGAVQSLFNIVNNSKLVLSPQELVDCTINANGCKGGNPIYAFNYVRDH 
BmCP-1 clone QGACGSCWAFATAGAVQSLFNIVNNSKLVLSPQELVDCTINANGCKGGNPIYAFNYVRDH 
  ************************************************************ 
 
B.microti CP-1 GLCTLNDYPYVGFQQKCSSSSCKHKIPIKNKMLVTSGFDIALAQGSPMVVGIDANGPFQH 
BmCP-1 clone GLCTLNDYPYVGFQQKCSSSSCKHKIPIKNKMLVTSGFDIALAQGSPMVVGIDANGPFQH 
  ************************************************************ 
 
B.microti CP-1 YSHGIFEAPCTPGTSNHAVLLVGYGVDKETGKKYWVIKNSWGPDWGEKGYARILRSDDGN 
BmCP-1 clone YSHGIFEAPCTPGTSNHAVLLVGYGVDKETGKKYWVIKNSWGPDWGEKGYARILRSDDGN 
  ************************************************************ 
 
B.microti CP-1 GADCNLTKFGL 
BmCP-1 clone GADCNLTKFGL 
  *********** 
 
 
Fig. 7. Alignment of cloned Babesia microti Cysteine Protease-1 predicted amino 
acid sequences.  The amino acid sequence of the hydrophilic region from the previously 
identified B. microti Cysteine Protease-1 (B. microti CP-1) gene is aligned with the 
obtained sequence of the region cloned into pCMVCD5flag (BmCP-1 clone). Amino 
acids identical in both sequences are indicated by stars (). 
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B.microtiAMA-1 ALANARPAHRKIVHKHKNSGAKPRHQAKKHVNITEEDDEDGEVYEEDEEDDYEDTDYEEL 
BmAMA-1 clone ALANARPAHRKIVHKHKNSGAKPRHQAKKHVNITEEDDEDGEVYEEDEEDDYEDTDYEEL 
 ************************************************************ 
 
B.microtiAMA-1 EFKPIGDERDNPWESYMEKFNIPKVHGSGVYVDLGKNGTFNGKKYRMVAGKCPVFGKIIE 
BmAMA-1 clone EFKPIGDERDNPWESYMEKFNIPKVHGSGVYVDLGKNGTFNGKKYRMVAGKCPVFGKIIE 
 ************************************************************ 
 
B.microtiAMA-1 FSSGVDYLSPANDTANPAFGFPYTVPAGKTIRTNEIPKTSRGRISISKSAVQTDLISPVT 
BmAMA-1 clone FSSGVDYLSPANDTANPAFGFPYTVPAGKTIRTNEIPKTSRGRISISKSAVQTDLISPVT 
 ************************************************************ 
 
B.microtiAMA-1 AKTLKAYEYDGDDIFNCASYASELMMSSDRKSDYKYPFAFDLKTKTCHILYSPLQLIQGP 
BmAMA-1 clone AKTLKAYEYDGDDIFNCASYASELMMSSDRKSDYKYPFAFDLKTKTCHILYSPLQLIQGP 
 ************************************************************ 
 
B.microtiAMA-1 KYCDNDGKVDSGSSSMPCIKPVKDMSQEMVYGSSFIYRDWKNKCPNAAVADAIFGTWNGT 
BmAMA-1 clone KYCDNDGKVDSGSSSMPCIKPVKDMSQEMVYGSSFIYRDWKNKCPNAAVADAIFGTWNGT 
 ************************************************************ 
 
B.microtiAMA-1 ACVPIQNRRLFKASTPEICGQIVFKYSASDAPENYETKRSEGSKFANAISSGDLGAVAKI 
BmAMA-1 clone ACVPIQNRRLFKASTPEICGQIVFKYSASDAPENYETKRSEGSKFANAISSGDLGAVAKI 
 ************************************************************ 
 
B.microtiAMA-1 IMPVTNSRAHHSKGWGFNWANYDRNKRECGLIDEVPNCLVFKMGNIAFNSLGSPLEDDME 
BmAMA-1 clone IMPVTNSRAHHSKGWGFNWANYDRNKRECGLIDEVPNCLVFKMGNIAFNSLGSPLEDDME 
 ************************************************************ 
 
B.microtiAMA-1 NFPCEIKSFGYITKGNPNDINSYLISSTHRDMIPNDDGIETLNARSCSGYYGKIGAKESE 
BmAMA-1 clone NFPCEIKSFGYITKGNPNDINSYLISSTHRDMIPNDDGIETLNARSCSGYYGKIGAKESE 
 ************************************************************
  
 
 
Fig. 8. Alignment of cloned Babesia microti Apical Membrane Antigen-1 predicted 
amino acid sequences.  The amino acid sequence of the ectodomain from the previously 
identified B. microti Apical Membrane Antigen-1 (B. microti AMA-1) gene is aligned 
with the obtained sequence of the region cloned into pCMVCD5flag (BmAMA-1 clone). 
Amino acids identical in both sequences are indicated by stars (). 
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3.3 Confirmation of in vitro BmCP-1 and BmAMA-1 protein expression using 
immunohistochemistry 
To confirm the expression of the flag-tagged BmAMA-1 and BmCP-1 proteins, 
HEK 293A cells were transfected and expression verified through 
immunohistochemistry detecting the presence of the FLAG marker peptide (Fig. 9). 
 
 
 
 
Fig. 9.  Expression of Babesia microti FLAG-tagged CP-1 and AMA-1 proteins in 
HEK 293-A cells. Probed with ANTI-FLAG M2 Monoclonal Antibody alkaline 
phosphatase conjugate. (A) Cells expressing CP-1 (arrows), (B) control cells, (C) cells 
expressing AMA-1 (arrows) (400X).  
 
 
 
3.4 Identification of Babesia microti AMA-1 and CP-1 proteins 
 
The open reading frames of the B. microti AMA-1 and CP-1 genes in the 
expression vector pCMVCD5flag were expressed and affinity purified.  As shown in 
Fig. 10, a strong specific 54 kDa band was obtained from lysate of HEK293F cells 
transfected with the BmAMA-1 construct and a 48 kDa band was obtained from the 
lysate of cells transfected with the BmCP-1 construct.  The molecular size of both 
proteins is consistent with the expected size from the predicted amino acid sequence. 
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Fig. 10. Western blot analysis of ANTI-FLAG M2 Affinity purified Babesia microti 
AMA-1 and CP-1 expressed proteins. (A) FLAG-tagged B. microti AMA-1 protein 
migrating at approximately 54 kDA (Lane 1). FLAG-tagged Interleukin-4 positive 
control (Lane 2). (B). FLAG-tagged B. microti CP-1 protein migrating at approximately 
48 kDa. 
 
 
3.5 Analysis of parasitemia  
 
In order to examine the protective effects of the B. microti AMA-1 and CP-1 
DNA vaccines, mice were challenged with 107 B. microti-infected erythrocytes passaged 
from infected mice. By day 2 post-challenge, all mice developed a measurable 
parasitemia lasting until day 18 for the BmCP1 and BmAMA1 groups and until day 21 
for the BmCP1/BmAMA1 and the plasmid control groups.  The mean daily percent 
parasitemia values for each group (Fig. 11) have the highest mean peak parasitemia, 
20.04%, in the plasmid control group on day 9 and the lowest mean peak parasitemia, 
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7.42%, in the BmCP1 group on day 8.  Figure 12 shows parasitemia values for each 
individual over time, color-coded according to vaccine group. 
 
                                                                                                                                             
Fig. 11. Mean group percent parasitemias. 
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Fig. 12.  Individual parasitemia for each subject. 
 
 A repeated data analysis was used to analyze the data obtained from the 
observed parasitemias. The model for this analysis was: 
ijkijjikiijk edY )(  where i=1,2,3,4,  j=1,..,21 and k=1,…,5 i  i-th 
treatment effect, j  j-th time effect, ij)(  treatment-time interaction effect, ijke  is the 
error for every observation and considered independent and identically distributed (i.i.d), 
ikd  is the random effect of the subject (mouse) which is normally distributed with mean 
zero and variance decided from Akaike's information criterion (AIC) where ikd  is 
independent from ijke . After a check with the AIC, it was decided that the variance of 
the subject would be different in every time step. Therefore, there will be a diagonal 
covariance matrix of random effect for the subject in every time step. This choice can be 
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justified from Fig. 12 showing the individual parasitemias for each animal or from the 
table of estimated covariance (Table 2). 
 
Table 2  
Model Dimension for Covariance 
Model analysis table for selection of the proper covariance matrix for the error variance. 
 
Model Dimension
 a
 
 
Number of 
Levels 
 
Covariance 
Structure 
Number of 
Parameters 
Subject 
Variables 
Number of 
subjects 
Fixed Effects            Intercept                              1                                                       1 
                                 Vaccine                               4                                                       3 
                                 Days                                  21                                                     20 
                                 Vaccine * Days                  84                                                     60 
Repeated Effects     Days                                   21             Diagonal                          21             subject                     20 
Total                                                                  131                                                   105 
 
a Dependent Variable: Parasitemia  
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Table 3  
Type III Test of Fixed Effects: Parasitemia  
Results of a fixed effect model based on the chosen diagonal covariance matrix 
(parasitemia). 
 
 
Type III Test of Fixed Effects a 
 
Source 
Numerator 
df 
Denominator 
df 
 
F 
 
Sig. 
Intercept 
Vaccine 
Days 
Vaccine * Days 
1 
3 
20 
60 
82.554 
82.554 
19.013 
19.013 
197.271 
5.762 
16.065 
.907 
.000 
.001 
.000 
.629 
  
a Dependent Variable: Parasitemia 
 
The analysis of variance table (Table 3) shows that there is no significant 
interaction between time and vaccine.  The mean group parasitemias given in Fig. 11 
indicate interaction; however, Table 3 proves that this is because of variability as 
opposed to real interactions. The main effect of the vaccines is statistically significant, 
meaning that statistically the vaccines react differently compared to each other and the 
control group.  A least significant difference (LSD) test of all the possible vaccine 
comparisons is shown in Table 4. 
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Table 4  
Pairwise Comparison: Parasitemia 
Pairwise comparison of parasitemia for each experimental group. 
Based on estimated marginal means 
* The mean difference is significant at the .05 level. 
a Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
b Dependent Variable: Parasitemia 
 
Based on the information in Table 4, it can be concluded that the mice vaccinated 
with BmCP1 developed a statistically lower parasitemia than any of the other groups, 
including the control group (P = .000). Mice vaccinated with BmAMA1 also developed 
a statistically lower parasitemia compared to the control group (P = .037); however, 
Pairwise Comparison 
b
 
 
 
(I) Vaccine         (J) Vaccine 
 
 
Mean 
Difference 
(I-J) 
 
 
Std. Error 
 
 
df 
 
 
Sig. 
a
 
 
95% Confidence Interval 
for Difference 
a 
 
Lower 
Bound 
Upper 
Bound 
 
BmAMA1             BmCP1 
                          BmAMA1/CP1 
               Control 
 
BmCP1               BmAMA1 
                         BmAMA1/CP1 
                            Control 
 
BmAMA1/CP1    BmAMA1 
               BmCP1 
               Control 
 
Control               BmAMA1 
                            BmCP1    
                            BmAMA1/CP1 
 
1.331* 
-.292 
-1.339* 
 
-1.331* 
-1.624* 
-2.730* 
 
.292 
1.624* 
-1.107 
 
1.339* 
2.730* 
1.107 
 
.662 
.662 
.662 
 
.662 
.662 
.662 
 
.662 
.662 
.662 
 
.662 
.662 
.662 
 
82.554 
82.554 
82.554 
 
82.554 
82.554 
82.554 
 
82.554 
82.554 
82.554 
 
82.554 
82.554 
82.554 
 
.047 
.660 
.037 
 
.047 
.016 
.000 
 
.660 
.016 
.098 
 
.037 
.000 
.098 
 
.015 
-1.608 
-2.715 
 
-2.647 
-2.940 
-4.046 
 
-1.024 
.308 
-2.423 
 
.083 
1.415 
-.209 
 
2.647 
1.024 
-.083 
 
-.015 
-.308 
-1.415 
 
1.608 
2.940 
.209 
 
2.715 
4.046 
2.423 
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based on the confidence intervals, it is obvious that the BmCP1 vaccine was more 
effective than AMA-1 at providing protection against B. microti challenge.  
 
3.6 Analysis of packed cell volume 
As with the analysis of parasitemia, a repeated data analysis model was used to 
analyze the PCV data obtained from the animals within each group (Fig. 13 and Fig. 14). 
From day 0 to day 15, the mean PCV of all the groups decreased. The substantial drop in 
PCV between days 5-10 correlates with the mean peak parasitemias for all groups, 
which occurred between days 7 and 12. This time frame correlates with previous 
published reports of B. microti infections (Hu et al., 1996).  The group that had the least 
drop in PCV was the group that received BmCP1. The mean PCV of the BmCP1 group 
was considered significantly different from that of the control group (P = .011).  The 
group that had the greatest drop in PCV was the control group. After the mice appeared 
to be clear of parasitemia, a final PCV was determined. The BmCP1 group and the 
BmAMA1 had the PCV returning to normal levels at a faster rate than all other groups 
(Fig. 13). The PCVs of the control group remained lower than all other groups (Fig. 13).  
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Fig. 13.  Mean group packed cell volume (PCV). 
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Fig. 14.  Individual PCV for each subject. 
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The model used was: ijkijjikiijk edY )(  where i=1,2,3,4,  
j=1,…,6 and k=1,…,5 i  i-th treatment effect, j  j-th time effect, ij)(  treatment-time 
interaction effect, ijke  is the error for every observation and is considered i.i.d., ikd  is the 
random effect of the subject (mouse) which is normally distributed with mean zero and 
variance decided from AIC criteria (shown in Table 5).   
 
Table 5 
Comparison of Different Statistical Models 
Measure of the goodness of fit for different statistical models. 
 
 
 
 
 
 
From the above table, the smallest AIC is met when the assumption is made of 
diagonal covariance matrix within the subject error. The criteria chose the optimal 
covariance matrix in terms of best fit and over-parameterization. This choice can be 
justified from the variability seen in Fig. 14 or from the table of estimated covariance 
(Table 6). 
 
 
 
 
 
AR1 
 
CS 
 
DIAG 
 
-2 Restricted Log 
Likelihood 
 
Akaike's Information 
Criterion (AIC) 
 
605.862 
 
 
605.862 
 
612.157 
 
 
612.157 
 
560.454 
 
 
572.454 
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Table 6  
Type III Test of Fixed Effects: PCV 
Results of a fixed effect model based on the chosen diagonal covariance matrix (packed 
cell volume). 
 
 
Type III Test of Fixed Effects a 
 
Source 
Numerator 
df 
Denominator 
df 
 
F 
 
Sig. 
Intercept 
Vaccine 
Days 
Group * Days 
1 
3 
5 
15 
49.230 
49.230 
20.764 
20.764 
12919.630 
3.005 
44.057 
.918 
.000 
.039 
.000 
.559 
 
a  Dependent Variable: PCV 
 
From Table 7, BmCP1 and BmAMA1/CP1 as well as BmCP1 and the plasmid 
control are statistically different at a significance level of 0.05. Based on the available 
information, it cannot be concluded that BmCP1 is superior to BmAMA1 even though 
the P-Value is close to 0.1. More observations (a larger sample size), are needed to reject 
the null hypothesis that the vaccines are the equivalent to each other and the control. 
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Table 7 
Pairwise Comparison: PCV  
 
Comparison of PCV for each experimental group. 
 
Based on estimated marginal means 
* The mean difference is significant at the .05 level. 
a Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments) 
b Dependent Variable: PCV 
                
  
 
 
Pairwise Comparison 
b
 
 
 
(I) Vaccine         (J) Vaccine 
 
 
Mean 
Difference 
(I-J) 
 
 
Std. 
Error 
 
 
df 
 
 
Sig. 
a
 
 
95% Confidence 
Interval for Difference
a 
 
Lower 
Bound 
Upper 
Bound 
 
BmAMA1            BmCP1 
                            BmAMA1/CP1 
                Control 
 
BmCP1               BmAMA1 
                            BmAMA1/CP1 
                            Control 
 
BmAMA1/CP1    BmAMA1 
                  BmCP1 
                 Control 
 
Control               BmAMA1 
                            BmCP1    
                            BmAMA1/CP1 
 
-2.000 
1.300 
1.433 
 
2.000 
3.300* 
3.433* 
 
-1.300 
-3.300* 
.133 
 
-1.433 
-3.433* 
-.133 
 
1.299 
1.299 
1.299 
 
1.299 
1.299 
1.299 
 
 1.299 
1.299 
1.299 
 
1.299 
1.299 
1.299 
 
49.230 
49.230 
49.230 
 
49.230 
49.230 
49.230 
 
49.230 
49.230 
49.230 
 
49.230 
49.230 
49.230 
    
.130 
.322 
.275 
 
.130 
.014 
.011 
 
.322 
.014 
.919 
 
.275 
.011 
.919 
 
-4.611 
-1.311 
-1.178 
 
-.611 
.689 
.822 
 
-3.911 
-5.911 
-2.478 
 
-4.044 
-6.044 
-2.744 
 
.611 
3.911 
4.044 
 
4.611 
5.911 
6.044 
 
1.311 
-.689 
2.744 
 
1.178 
-.822 
2.478 
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4. DISCUSSION AND SUMMARY 
 
 
Babesia bovis is an arthropod-transmitted apicomplexan pathogen infecting cattle 
in tropical and subtropical regions of the world. Babesia bovis infections cause 
significant morbidity and mortality resulting in devastating production and economic 
losses. Control of this parasite remains an important issue for cattle industries 
worldwide. Although B. bovis and the vector responsible for transmission were 
eradicated from the U.S. by 1943, reintroduction is a significant threat. Attenuated forms 
of the parasite have been used for effective control in endemic areas such as Australia; 
however, due to their drawbacks noted previously (Introduction, page 13), the 
development of recombinant vaccines is a more promising method for protection. The 
recently sequenced B. bovis genome (http://www.ncbi.nlm.nih.gob/BLAST/) allows the  
identification of a number of vaccine candidates, including Cysteine Protease-2 and 
Apical Membrane Antigen-1.  
Cysteine proteases are critical to the pathogenicity of many parasites. 
Recombinant cysteine protease antigens have been used to stimulate 
a strong Th1 immune response, increase the rate of survival of infected animals, and 
inhibit parasites (Engle et al., 1998; McKerrow et al., 1999; Somanna et al., 2002; 
Rosenthal, 2004). Bart et al. (1997) reported that a cysteine protease-deficient mutant 
of Leishmania mexicana greatly reduced parasite infectivity to macrophages in vitro. 
The prophylactic potential of cysteine proteases has also been used in both cutaneous 
Leishmaniasis and visceral Leishmaniasis models of mice and dogs (Rafati et al., 2001; 
Rafati et al., 2005). Khoshgoo et al. (2008) reported that the parasite load of mice 
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vaccinated with Leishmania infantum Cysteine Proteinase Type III was significantly 
lower than control animals. Similar studies involving Trypanosoma cruzi, Toxoplasma 
gondii and Plasmodium spp. have given encouraging results in the use of cysteine 
proteases as vaccine targets (McKerrow et al., 1999; Teo et al., 2007).  In the current 
study, to optimize exposure of specific T- cell receptors, the hydrophilic region of 
B. microti CP-1 was selected for expression in the pCMVCD5Flag vector.    
AMA-1 is a microneme protein that is highly conserved among apicomplexan 
parasites including Plasmodium spp. Toxoplasma gondii and Babesia spp. (Chesne-Seck 
et al., 2005). Experimental evidence has shown that Plasmodium spp. AMA-1 is 
involved in merozoite invasion of erthrocytes, and is essential to the proliferation and 
survival of malaria (Triglia et al., 2000). Plasmodium AMA-1 is a highly immunogenic 
protein. The majority of individuals exposed to malaria develop anti-AMA-1 antibodies 
after only a few exposures (Riley et al., 2000).  Toxoplasma gondii tachyzoites depleted 
of TgAMA1 are severely compromised in their ability to invade host cells, providing 
direct evidence that AMA-1 functions during host cell invasion (Mital et al., 2005). For 
this study, the ectodomain of B. microti AMA-1 was incorporated into the 
pCMVCD5Flag expression vector. The ectodomain is the area of the protein will be 
exposed on the parasite cell surface so it is the most likely region to encounter antibody, 
and therefore the best candidate for inclusion in the vector. 
The choice of vaccine targets for this study was predicated on considerable 
evidence of the potential of both cysteine protease and AMA-1 to be effective vaccine 
components.  Cysteine proteases have long been known for their involvement in 
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parasitic disease; however, they are also known for their involvement in tumor 
progression, arthritis, osteoporosis and virus replication (Selzer et al, 1999; Turk et al., 
2004). Targeting cysteine proteases appears to be a promising strategy in the 
development of new chemotherapy for a number of diseases, including babesiosis. 
Immunization of animals with the ectodomain of AMA-1 induces protective immunity 
against challenge with asexual blood-stage malaria parasites in murine and simian 
models (Crewther et al., 1996; Stowers et al., 2002) and, thus, has recently been tested in 
a phase II clinical vaccine trial for P. falciparum-human malaria (Sagara et al., 2009).   
 To create an efficient detection and purification system based upon fusion 
polypeptides, a specific sequence encoding for the FLAG marker peptide (amino acid 
sequence, DYKDDDDK) is included at the C-terminus of the pCMV-2CD5Flag vector 
(Sigma-Aldrich). Because of its hydrophilic nature, the FLAG peptide is likely to be 
located on the surface of a fusion protein making it readily accessible to anti-FLAG 
antibodies (McIlhinney, 2004). Our lab has yet to obtain either B. microti CP-1 and 
AMA-1 antigen in substantial amounts, thus we have no specific antibody raised against 
these proteins. Adding a FLAG-tag to these recombinant proteins has allowed us to 
detect them using antibody against the FLAG sequence.  
BALB/c mice are useful for immunology research involving protozoan parasites 
because they are highly susceptible to trypanosomiasis, toxoplasmosis, various forms of 
leishmaniasis and malaria as well as infections from B. microti and Babesia rodhaini 
(Shimada et al., 1996; Rafati et al., 2000; Narum et al., 2000; Boyle et al., 2007; 
Antoine-Moussiaux et al., 2008). BALB/c mice are an inbred strain and are therefore 
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isogenic (genetically identical). These mice are considered ideal for experimental work 
because they do not possess the genetic variability that often contributes to inconsistent 
data. Babesia bovis is host specific for bovines, thus cannot infect mice or other small 
animal laboratory models.  Undoubtedly, differences will be seen between murine 
models of B. microti and bovine B. bovis. However, this shouldn’t be considered as an 
obstacle to studying bovine babesiosis through mouse models because the advantage lies 
in the highly conserved genomes found among Babesia spp.  
Subunit vaccines generally require the addition of an adjuvant to be effective 
(Singh and O’Hagan, 2002). Given their potent immunostimulatory capacity, bacterial 
substances are an excellent source of potential adjuvants (Klinman et al., 1999; Klinman 
et al., 2004). Bacterial cell wall peptidoglycans enhance the immune response without 
themselves being highly immunogenic. The demonstration that mycobacterial DNA had 
adjuvant activity led to the discovery that the adjuvant activity is correlated with a higher 
content of CpG motifs (Introduction, page 21) present in bacterial nucleic acids. DNA 
that contains CpG motifs is one of the most potent cellular adjuvants, increasing antigen-
specific immune responses 5 to 500-fold (Klinman et al., 2004). CpG acts via activation 
of a Toll receptor pathway thereby promoting the production of T helper 1 (Th1) and 
pro-inflammatory cytokines (van Duin et al., 2006). Plasmid DNA, apart from encoding 
the antigen, can also be optimized to include adjuvants such as CpG. The expression 
vector used in this study incorporates a CpG motif as its adjuvant.  
The use of a priming dose of DNA constructs followed by a recombinant protein 
boost has been reported to be effective in invoking T-cell production against 
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Plasmodium berghei in mice and P. falciparum in Rhesus monkeys (Schneider et al., 
1999; Jones et al., 2001; Dunachie and Hill, 2003). However, this method of vaccination 
requires ample amounts of recombinant protein. Despite having high protein expression 
in an in vitro cell model prior to use in this study, sufficient amounts of the recombinant 
proteins from the BmCP1 and BmAMA1 plasmid constructs used in this study could not 
be obtained through affinity purification. Lysates of BmCP1 and BmAMA1 proteins 
expressed in HEK293F cells were sampled prior to loading on the purification column 
and samples of the agarose beads from the loaded purification column indicated the 
presence of the proteins in both the lysates and the columns by western blotting. 
However, western blotting also indicated that the protein was not successfully eluted in 
the expected amounts. There are various reasons that might explain why the proteins are 
not being purified with high yield: 1) The elution conditions (pH) are not sufficient to 
disrupt the binding to remove the protein from the column; 2) The proteins may fold in 
such a way that they are bound too tightly to be effectively eluted and 3) The ratio of 
resin to protein was not optimal.   
Biolistic particle delivery systems such as the Helios Gene Gun (Bio-Rad) have 
been used successfully to deliver DNA vaccines to humans and experimental animals 
(Larregina, 2000; Cesco-Gaspere et al., 2008). By accelerating DNA-particle complexes 
into target tissue, DNA is effectively introduced without the pain and discomfort 
associated with needles and without the stress/danger of anesthetic. Studies indicate that 
DNA immunization using conventional needle methodologies is less successful than 
gene gun immunization in non-human primates and humans. As reported in HIV, DNA 
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immunization via needle injection is only effective in priming human immune 
responses when it is given in high (mg) DNA doses (Wang et al., 2008a). Gene gun 
technology enhances DNA vaccination because it requires only a small amount to elicit a 
protective immune response, usually less than 2 µg (Pertmer et al., 1995). DNA 
immunization by the gene gun-mediated delivery approach has been the only vaccination 
technique able to elicit protective levels of immunity in healthy, adult human volunteers 
without the use of another vaccine system, i.e. target protein with adjuvant, as a boost 
(Wang et al., 2008b). 
In this study, the protective response to challenge B. microti infection that was 
induced by gene gun DNA vaccination by BmCP1, BmAMA1, or BmCP1 and 
BmAMA1 combined was compared based on parasitemia and clinical presentation upon 
challenge infection. The BmCP1 gene and the BmAMA1 gene vaccines induced 
enhanced protection against B. microti parasitemia compared to that of the plasmid 
control vaccine, P = 0.000 and 0.037, respectively. Although the BmCP1 group and the 
BmAMA1 group were both significantly superior to the control at protecting the mice 
against progression of the parasitemia, the BmCP1 vaccine induced greater protection 
than the BmAMA1 vaccine group (P = 0.047). BmCP1 vaccine was also significantly 
more effective than BmCP1/BmAMA1 vaccine (P = 0.016); however, there was no 
significant difference between BmAMA1 and the BmCP1/BmAMA1 vaccines (P = 
0.660). This concludes that BmCP1, and to a lesser extent BmAMA1, are effective in 
decreasing the mean parasitemia of mice challenged with B. microti.  However, the 
ability to reduce parasitemia is irrelevant if it fails to prevent clinical manifestations of 
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the disease. Evaluation of the packed cell volumes of the mice throughout the vaccine 
showed that only BmCP1 was able to reduce this effect with any level of significance (P 
= 0.011).  
It was anticipated that the dual vaccine, BmCP1 and BmAMA1 combined, would 
provide the best protection against B. microti challenge.  Optimal protective responses 
from Gene Gun delivery have been reported to be dependent on the delivery of a 
sufficient number of DNA-coated particles, as well as how much DNA coats the gold 
particles (Eisenbraun et al., 1993).  It is possible that the combination vaccine containing 
a total of 4 µg/shot was too much DNA to properly precipitate onto the 0.5 mg of 1.6 µm 
diameter gold beads used. Future experiments might incorporate more beads or 0.5 mg 
of smaller beads to increase the surface volume, thereby allowing better binding of the 
DNA. In the future, optimization of DNA binding on the beads could be evaluated by in 
vitro transfection of cell lines to quantitate expression of the recombinant proteins.  
Using smaller beads also might facilitate their dispersal on the cartridges used to deliver 
the dose so that a more uniform dose is obtained.  A wide range in response to challenge 
was seen in all of the vaccine groups, which is contrary to the expected results in an 
inbred mouse strain.  This may have been in part a result of uneven dispersal of the 
DNA-gold complexes as they were coated in a long tube that was then cut into 
individual dose cartridges for use.   
Based on the work of previous researchers and observations of infected BALB/c 
mice in this laboratory, animals were challenged with 107 infected erythrocytes (Iseki et 
al., 2007). However, because of the rapid onset of parasitemia it is suspected that 
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this dose may have been too high. The parasites used for challenge were collected 
from immume-deficient C.B-17/IcrHsd-Prkdc-scid mice. Although 107 infected 
erythrocytes were administered, the number of parasites per erythrocytes was not 
quantified. C.B-17/IcrHsd-Prkdc-scid mice lack lymphocytes therefore, the parasite 
replicates at a higher rate in the erythrocytes of these mice resulting in more parasites 
within a single erythrocyte compared to immunocompetent BALB/c mice. In future, the 
challenge dose should be determined based on parasite number as much as possible.  
This study would be enhanced by the inclusion of assays to determine immune 
responses of the vaccinated mice and confirmation that cysteine protease and 
AMA-1 are expressed in vivo.  Ideally, seroconversion and cytokine production in the 
recipients should be examined during the course of the trial.  For this trial, recombinant 
antigen and specific antibody were not available in order to design assays to evaluate the 
serologic response to vaccination.  The standard assay used to evaluate seroconversion is 
an ELISA assay. Cytokine quantification, particularly the production of IFN-γ, is best 
measured by an ELISPOT assay. Both the ELISA and ELISPOT assay require specific 
antigen in order to produce the necessary data. If an antigen was available and serology 
had been possible, the dosing of the vaccines could have been optimized. The 
vaccination protocol used in this study was based on successful Gene Gun administered 
vaccines against apicomplexan parasites (Ishii et al., 2006; Dautu et al., 2007). Ideally, 
titer levels should be determined by ELISA assays throughout the course of vaccination. 
Recombinant protein expression in the recipients was not determined during this 
study.  Larger groups of mice would need to be employed so that animals could be 
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euthanized at critical timepoints throughout the trial and evaluated for specific protein 
expression.  This might be accomplished through western blotting (Dautu et al., 2007).  
Typically, a larger sample size leads to increased precision when making 
statistical inferences. This study required daily data collection, and the sample size was 
limited based on cost and available manpower. If repeated, a large sample size should be 
utilized to ensure greater statistical significance. 
While it is obvious that the pBmCP1 and pBmAMA1 pDNA vaccines were able 
to reduce the mean parasitemia of the vaccinated animals, it did not confer total 
protection. Ideally, the most successful vaccine would confer protection against the 
establishment of infection, rather than just reducing the number of parasites. The 
multiallelic P. falciprum AMA1-C1 vaccine currently in Phase II clinical trials is an 
equal mixture of the correctly folded ectodomain portion of recombinant AMA-1 
proteins (Sagara et al., 2009). The success seen with this vaccine suggests that 
recombinant proteins are most effective at conferring total protection against protozoan 
parasites. Future efforts should focus on obtaining the recombinant BmCP1 and 
BmAMA1 proteins in high yield for incorporation into a vaccination either alone or in 
conjunction with BmCP1 and BmAMA1 plasmids. 
In conclusion, although a significant protective response was seen 
using B. microti CP-1 and AMA-1 plasmid constructs, vaccine optimization is necessary 
to confer total protection against the parasite. Secondly, these results indicate future 
application to a potential B. bovis vaccination. This laboratory was able to 
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obtain B. bovis Cysteine Protease-2 and Apical Membrane Antigen-1 for use towards the 
development of a bovine babesiosis vaccine.  
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